European Neuropsychopharmacology (v.20, #S3)
P.3.c.039 Effects of neuroleptic treatment on oxidative stress parameters in schizophrenia patients by A.S. Ivanova; L.P. Smirnova; N.M. Krotenko; A.V. Semke (S480-S481).
P.3.c.038 Quetiapine and norquetiapine efficacy in axiety and depression in major psychosis: a pharmacokinetic approach by M. Mauri; B. Dell'Osso; M. Buoli; S. Paletta; D. Moliterno; S.R. Bareggi; A.C. Altamura (S480).
P.3.c.040 Treatment adherence and tolerability of high doses of risperidone longacting injectable in severe schizophrenic patients by J.j. Fernandez-Miranda; I. Gancedo-Alvarez; M. Redondo-Alvarez; V. Carames-Garcia; A. Sanchez-Garcia (S481).
P.3.c.041 A randomized, double-blind study of paliperidone palmitate and risperidone long-acting therapy in schizophrenia by G. Pandina; R. Lane; S. Gopal; C. Gassmann-Mayer; D. Hough; B. Remmerie; G. Simpson (S481-S482).
P.3.c.042 Antipsychotic polypharmacy and excessive doses are not associated with attentional flexibility in schizophrenia by D. Kontis; S. Kleisas; E. Theochari; S. Kalogerakou; A. Andreopoulou; S. Vassilouli; S. Papakonstantinou; C. Karouzos; E. Tsaltas (S482).
P.3.c.037 A prospective randomized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia by C. Tessier; D. Hoeben; P. Korcsog; D.J.H. Niehaus; K. Aadamsoo; A. Ücok; M. Franco; P. Theodoropoulou; R. Salinas; A. Schreiner (S479).
P.3.c.036 Antipsychotics prescribing pattern of patients with schizophrenia admitted to Korean general hospital: 2001 to 2008 by H.J. Choi; S.H. Jung; C.E. Kim (S478-S479).
P.3.c.032 Long-acting risperidone injection versus conventional depots in chronic psychotic patients: a 54 months study by S.L. Romero Guillena; N. Casas Barquero; J.L. Velez Noguera; R. Fernandez-Villamor Ortiz (S476).
P.3.c.031 Risk of metabolic, cardiologic, and endocrinologic abnormalities in patients under long-term antipsychotic treatment by G. Cerveri; A. Mazzocchi; L.S. Volonteri; C. Mannussakis; C. Mencacci (S475-S476).
P.3.c.033 Predictors for treatment response in non-acute patients with schizophrenia by A. Schreiner; C. Tessier; D. Hoeben; M. Lahaye; J. Pfeil; J. Peuskens; F. Rosa; D. Naber; E. Smeraldi; S. Djukic-Dejanovic (S477).
P.3.c.034 A 6-month naturalistic study of outcome in schizophrenic out-patients, treated with olanzapine by M. Krzystanek; I. Krupka-Matuszczyk (S477-S478).
P.3.c.035 QUALITY: a non-interventional study evaluating QOL in schizophrenic patients treated with atypical antipsychotics by J. Peuskens; C. Taeter; V. Duquenne (S478).
P.3.c.043 Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia by I. Espiño Díaz (S483).
P.3.c.044 Antipsychotic polypharmacy in a community psychiatric clinic by C. Willis; K.S. Naidoo; P. Sawhney (S483-S484).
P.3.c.053 Reasons for switching between antipsychotic drug treatments – the international antipsychotic drug substitution registry by B. Galinska-Skok; P. Paterakis; M. Bubrovszky; P. Thomas; G. Perdriset; L. Pani (S488-S489).
P.3.c.052 Overdose of paliperidone: a case report by J.M. Olivares; C. Cinos; C.P. Losada; F.J. Gutiérrez; M. López (S487-S488).
P.3.c.054 Effect of the DRD2 Taq 1A polymorphism on perospirone and aripiprazole efficacy for Japanese schizophrenia patients by Y. Takekita; M. Kato; M. Wakeno; S. Nonen; S. Tetsuo; S. Sakai; A. Suwa; G. Okugawa; T. Kinoshita (S489).
P.3.c.055 Asenapine: short-term tolerability, safety, and pharmacokinetic profile in older patients with psychosis by S. Dubovsky; C. Frobose; P. Phiri; J. Panagides (S489-S490).
P.3.c.056 Prolactin elevation induced by antipsychotics in first episode psychotic patients by R. Perez-Iglesias; I. Mata; M.T. Garcia-Unzueta; J.A. Amado; O. Martinez-Garcia; J.L. Vazquez-Barquero; B. Crespo-Facorro (S490).
P.3.c.051 The effect of ziprasidone on the QTc interval when used in combination with lithium, valproate or lamotrigine by H. Meltzer; O.N. Karayal; J. Miceli; S. Kolluri; C. O'Gorman (S487).
P.3.c.050 Interaction between polymorphisms of oxidative enzymes and susceptibility to tardive dyskinesia in psychiatric patients by S.A. Ivanova; A.F.Y. Al Hadithy; P. Pechlivanoglou; A.V. Semke; O.Y. Fedorenko; L.A. Levchuk; E.G. Kornetova; J.R.B.J. Brouwers; R. Bruggeman; A.J.M. Loonen (S486-S487).
P.3.c.046 Efficacy and safety of JNJ 37822681, a fast dissociating D2 receptor antagonist, in the treatment of schizophrenia by M. Schmidt; L. Janssens; J. Kent; I. Anghelescu; G. Hüsken; V. Sinha; E. Mannaert (S484-S485).
P.3.c.045 Neuroleptic malignant syndrome after addition of ziprasidone to long-term treatment with risperidone by M. Markopoulou; K. Bobotas; V. Theodori (S484).
P.3.c.047 Six-months clinical trial of paliperidone extended-release in schizophrenia patients by E. Kim (S485).
P.3.c.048 Treatment with antipsychotics in hospitalised patients with maniac episode by M.C. Garcia Mahia; M. Vidal Millares; M. Gonzalez Santos; C. Armas Barbazan (S485-S486).
P.3.c.049 Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia by T. Jun; Y. Jeon; H. Lee; K. Lee (S486).
P.3.c.030 Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia by T. Sumiyoshi; M. Tsunoda; Y. Higuchi; T. Itoh; T. Seo; H. Itoh; M. Suzuki; M. Kurachi (S475).
P.3.c.029 A study to examine the efficacy and safety of amisulpride according to the different initial dosages in schizophrenia by J.H. Lee; K.H. Lee; J.O. Song; S.J. Lee; D.K. Lee (S474-S475).
P.3.c.011 Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study by H. Detke; P.J. Weiden; T. Lambert; P.M. Llorca; M. Choukour; S.B. Watson; E. Brunner; H. Ascher-Svanum (S464).
P.3.c.010 Risperidone and olanzapine comparison for weight changes in a 24 months open extension study by D. Begic; S. Bise; O. Cemalovic (S463).
P.3.c.012 Paliperidone for the treatment of hyperactive delirium: short-term, open-label trial by C. Han; H.K. Yoon; Y.H. Ko (S464-S465).
P.3.c.013 Risperidone in the treatment of depressive episodes and drug induced delirium in a patient with somatic comorbidity by S. Bise; D. Begic; B. Kurtovic (S465).
P.3.c.014 The impact of the subjective response to antipsychotics on the course of illness in schizophrenic patients by S. Murawiec (S465-S466).
P.3.c.009 Effects of switching to risperidone long-acting injection on cognitive function in schizophrenia by H. Suzuki; Y. Inoue; M. Otomo; Y. Kawaguchi; K. Gen (S463).
P.3.c.008 Correlation between psychotic symptoms and sleep disturbances in schizophrenia by J. Leszczynska; A. Paliga; J. Wieczorek; K. Krysta; I. Krupka-Matuszczyk (S462).
P.3.c.004 Anticholinergic prescribing patterns in patients receiving treatment with antipsychotic medication by F. Oosthuizen; K. du Toit; A.N. Khumalo; N.N.P. Shinga; T. Pillai; K. Pillay; S. Kanhai; T.S. Nhlapo (S460).
P.3.c.003 A randomized, controlled study to evaluate quetiapine fumarate in improving sleep quality of schizophrenia by B. Zhang; F.J. Jia; P. Zhou (S459-S460).
P.3.c.005 Association of antipsychotic polypharmacy with health service cost – a Danish register-based cost-minimisation analysis by L. Baandrup; J. Sørensen; H. Lublin; M. Nordentoft; B. Glenthøj (S460-S461).
P.3.c.006 Olanzapine in the treatment of anorexia nervosa: a case report by A. Capasso; C. Petrella; W. Milano (S461).
P.3.c.007 Compliance of outpatients using long acting antipsychotics with supportive outreaching: a matched case control study by H. Van Loon; H. Vandenbroele; S. De Bruyne; A. Wybo; M. Glorieux; V. Dubois; B. Gillain; J. Peuskens (S461-S462).
P.3.c.015 Haloperidol versus atypical antipsychotics in the long-term treatment of schizophrenia by A.C. Altamura; M. Buoli; M.C. Mauri; B. Dell'Osso (S466).
P.3.c.016 Cognitive functions and dosage of antipsychotic drugs in Japanese schizophrenia patients by H. Hori; R. Yoshimura; A. Katsuki; K. Hayashi; A. Sugita; W. Nakano; J. Nakamura (S466-S467).
P.3.c.025 Heart rate variability in patients with chronic schizophrenia switching from risperidone to paliperidone by T.T. Chen; J.Y. Chen; Y.C. Wang; H.S. Yeh; G.H. Mo; I.C. Lai (S472).
P.3.c.024 Prevalence of and factors associated with nonadherence to antipsychotic drugs in patients with schizophrenia by S. Suttajit; S. Pilakanta (S471-S472).
P.3.c.026 Risperidone depot versus zuclopenthixol depot for schizophrenia and schizophrenialike psychoses: real world outcomes by V. Fricchione Parise; G. Balletta; G. Manna (S472-S473).
P.3.c.027 The influence of DRD2 and endothelial nitric oxide synthase (eNOS) polymorphisms, prolactin and antipsychotics on sexual function in schizophrenic patients by X.R. Zhang; Z.J. Zhang; R.X. Zhu; Y.G. Yuan; T.A. Jenkins; G.P. Reynolds (S473).
P.3.c.028 Olanzapine in treatment of delusional disorders by N. Zivkovic; D. Pavicevic; G. Djokic; M. Nenadovic; N. Nenadovic; J. Lekovic (S473-S474).
P.3.c.023 Glycine plasma levels are not a useful predictor of recovery in patients treated with glycine and neuroleptics by D. Strzelecki; J. Rabe-Jablonska (S470-S471).
P.3.c.022 Comparison of patients treated with antipsychotics and psychoeducation and those treated with antipsychotics only by C. Istikoglou; D. Foutsitzis; G. Theodorakopoulos; P. Kanellos; N. Polonifis; A. Vlavianou; D. Vlissides; K. Michelidakis (S470).
P.3.c.018 The characteristics of pharmacotherapy for inpatients with schizophrenia: a multicentre comparative study in Asia by W. Nakano; R. Yoshimura; S. Yang; N. Shinfuku; S. Fujii; T. Hoshuyama; K. Sim; M. Chong; C. Tan; J. Nakamura (S467-S468).
P.3.c.017 Polish patients of the EUFEST study after 1 year antipsychotic treatment: drug discontinuation and metabolic syndrome parameters by J. Rabe-Jablonska; T. Pawelczyk; M. Jarema; M. Olajossy; J. Rybakowski (S467).
P.3.c.019 Community treatment orders and psychotropic medication: baseline data analysis for a one year follow up study (N= 200) by M.X. Patel; J. Matonhodze; M. Baig; J. Gilleen; J. Boydell; F. Holloway; D. Taylor; G. Szmukler; T.J. Lambert; A.S. David (S468-S469).
P.3.c.020 Olanzapine in serum and cerebrospinal fluid in patients with schizophrenia or schizoaffective disorder by E. Skogh; I. Sjödin; M. Josefsson; M.L. Dahl (S469).
P.3.c.021 Intramuscular aripiprazole versus injectable haloperidol in treatment of acute psychotic agitation by C. Istikoglou; A. Vlavianou; D. Foutsitzis; G. Theodorakopoulos; C. Polonifis; P. Kanellos; D. Vlissides (S469-S470).
P.3.c.057 Which patients switch antipsychotic medication? Data from the international Antipsychotic Drug Substitution Registry by P. Paterakis; B. Galinska-Skok; L. Pani; M. Bubrovszky; G. Perdriset; P. Thomas (S490-S491).
P.3.c.058 Clozapine-induced agranulocytosis in monozygotic twins and association with multidrug resistance gene MDR1 polymorphisms by A.E. Anil Yagcioglu; B. Cetin Ilhan; M.T. Goktas; M.O. Babaoglu; E. Uz; M.K. Yazici (S491).
P.3.e.010 Inhaled loxapine (AZ-004) rapidly improves acute agitation in patients with schizophrenia or bipolar disorder by J.V. Cassella; R.S. Fishman; D. Spyker (S512-S513).
P.3.e.009 Clinical analysis of the treatment of schizophrenia (CATS)-study: module assessment of sexual functions by M. Lautenschlager; W. de Millas; A. Lehmann; M. Lambert; K. Leopold; M. Franz; M. Deuschle (S512).
P.3.f.001 The impact of language and culture on the delivery of standardised rater training for the PANSS across seven countries by A. DeFries; C. Yavorsky; S. Liechti; M. Opler (S513).
P.3.f.002 Quantifying rater drift in a sample of standardised rater training events: Is PANSS reliability maintained over time? by A. DeFries; C. Yavorsky; M. Opler; L. Ramadhar; E. Ivanova; J. Gordon; S. Jovic; L. Yang (S513-S514).
P.3.f.003 Effect of clozapine on behavioural and cytokine profiles in rats with lipopolysaccharide and viral protein stimulation by H. Tejkalová; T. Ruml; M. Rumlová; J. Klaschka; S. Ruzicková (S514-S515).
P.3.e.008 Activation of the immune system with respect to cognitive functioning in schizophrenia by D. Frydecka; A. Beszlej; M. Szewczuk-Boguslawska; M. Zagdanska; L. Karabon; E. Pawlak; A. Kiejna (S511-S512).
P.3.e.007 Sexual activity and marital relationships in Tunisian schizophrenic patients: comparison with healthy controls by Y. El Kissi; M. Laaroussi; S. Gaabout; M. Ayachi; J. Nakhli; B. Ben Hadj Ali (S511).
P.3.e.003 Effectiveness of olanzapine standard oral and orally disintegrating tablets in a 1-year European observational study by F. Chartier; F. Rouillon; M. Lukasiewicz; S. Kraemer; Y. D'yachkova (S508-S509).
P.3.e.002 Aggressive behaviour among psychiatric inpatients in Psychiatric Hospital Hronovce (Slovakia) during the years 2006–2008 by M. Zelman; A.C.H. Das; A. Priscakova; J. Hudec (S508).
P.3.e.004 Standardisation of Korean version of Launay-Slade Hallucination Scale-Revised by H. Jung; Y. Kim; S.H. Kim; Y.S. Kim (S509).
P.3.e.005 Total blood cholesterol levels and serum creatine kinase activity in violent psychiatric inpatients by I. Reznik; S. Kertzman; H. Grinspan; M. Birger; N. Shlapnikov; H.Y. Meltzer (S509-S510).
P.3.e.006 The utility of the MMPI-2 and PAI for discriminating the patients with schizophrenia and depression in Korea by M.C. Park; Y.H. Ko; S.W. Oh; J.I. Park (S510-S511).
P.3.f.004 Coping strategies in individuals with serious and prolonged mental disorders by J. de Santiago Sastre; M.A. Sánchez Peña (S515).
P.3.f.005 Different forms of risperidone and haloperidol in sexual dysfunction among schizophrenic male patients by V. Sibinovic; S. Tosic-Golubovic; D. Gugleta; G. Selimovic; O. Zikic (S515-S516).
P.4.a.002 Does tobacco-smoking indicate an impulsive subtype of OCD? A case-control study by N.A. Fineberg; P. Sharma; T. Gale (S521).
P.4.a.001 Quality of life outcomes in obsessive-compulsive disorder: relationship to treatment response and symptom relapse by N.A. Fineberg; D.J. Stein; M. Legault; F. Marteau; E. Hollander (S520-S521).
P.4.a.003 Are tics an essential symptom of the obsessive-compulsive syndrome? by G. Hranov; N.A. Fineberg (S521-S522).
P.4.a.004 A comparison of different types of obsessions due to brain damage by S. Margaryan (S522-S523).
P.4.a.005 The prevalence of metabolic syndrome in patients with obsessive-compulsive disorder: a cross-sectional analysis by B. Goksan Yavuz; O. Karamustafalioglu; B. Bakim; B. Ozcelik; Y. Cengiz Ceylan; I. Erensoy; O. Tankaya; E. Turkyilmaz; H. Yumrukcal; E. Toprak (S523).
P.3.f.012 Psychoneuroimmune interactions in schizophrenia by O. Lobacheva; T.P. Vetlugina (S519-S520).
P.3.f.011 Nitric oxide inhibitor blocks methylphenidate-disruptive effect on prepulse inhibition and modifies limbic c-Fos expression by A. Issy Pereira; E.A. Del Bel (S519).
P.3.f.007 Atypical antipsychotics and effects of muscarinic and serotonergic receptor binding on insulin secretion in a rat model by M.K. Hahn; A.F. Chintoh; L. Lam; S.W. Mann; A. Giacca; P. Fletcher; G. Remington (S517).
P.3.f.006 Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviours in mice by A. Ortega-Álvaro; A. Aracil-Fernández; M.S. García-Gutiérrez; F. Navarrete; J. Manzanares (S516).
P.3.f.008 The relationship between insight and psychosis in schizophrenic Romanian patients by C. Crisan; C. Bondor; R. Macrea (S517-S518).
P.3.f.009 A raised glucocorticoid receptor alpha/beta expression ratio in monocytes of schizophrenic and bipolar patients by K. Weigelt; A. Spijker; R.C. Drexhage; J.M. Wijkhuijs; H.A. Drexhage (S518).
P.3.f.010 Continuous perfomance test dysfunction in delusional disorder: an fMRI investigation by F. Akyuz; S. Oflaz; A. Hamamci; Z. Firat; M. Cihangiroglu (S518-S519).
P.3.e.001 Facial emotion recognition deficit in schizophrenia: a replication study in Korean subjects by S.J. Lee; H.D. Rim; Y.W. Park; J.J. Lee; S.M. Jang; J.M. Woo; H.Y. Jo; K.U. Lee (S507-S508).
P.3.d.017 Psychotropic medication use profile and adequacy in elderly institutionalised population by B. Pascual Arce; M.C. Perez Navarro; L. Garcia Sanchez; N. Muro Perea; A. Sicras Mainar; M. Blanca Tamayo (S507).
P.3.c.067 One year study: efficacy of haloperidol versus risperidone in the treatment of schizoaffective disorder by D. Siladji Mladenovic; S. Drezgic Vukic; B. Golubovic; A. Ivezic (S496-S497).
P.3.c.066 Efficacy and safety of long-acting risperidone in schizophrenic stable subjects durring 6 months period by D.G. Gugleta; V.S. Slavkovic; S.T.G. Tosic Golubovic; V.S. Sibinovic; S.D. Stankovic (S496).
P.3.c.068 Psychopharmacological influence in effectiveness of psychotherapeutic programs in a psychiatric day hospital population by J. Aguado; O.M. Segurado (S497).
P.3.c.069 Dosage patterns – lessons learned from the e-STAR database in Czech Republic by E. Cesková; J. Kopriva (S497-S498).
P.3.d.001 Evaluation of clinical and functional outcomes in low-adherent to treatment patients with bipolar disorder in Spain by E. Medina; J.M. Montes; C. De Dios; A. Rodriguez (S498).
P.3.c.065 Comparison of multifactor dimensionality reduction (MDR) and neural network analysis: serotonergic system genes and antipsychotic response by V. De Luca; R.P. Souza; A. Tiwari; H.Y. Meltzer; S.G. Potkin; J. Volavka; J. Lieberman; J.L. Kennedy; A. Serretti (S495-S496).
P.3.c.064 Serum lipide profiles during antipsychotic treatment of schizophrenic subjects by V.S. Slavkovic; S.T.G. Tosic Golubovic; D.G. Gugleta; V.S. Sibinovic (S494-S495).
P.3.c.060 Aripiprazol in the treatment of catatonia -review of the literature and case reports by V. Voros; T. Tenyi (S492-S493).
P.3.c.059 Oxidative stress status in schizophrenic patients treated with typical versus atypical antipsychotics by M. Padurariu; I. Dobrin; C. Stefanescu; A. Ciobica; R.P. Dobrin (S491-S492).
P.3.c.061 Paliperidone palmitate response in acutely ill patients with schizophrenia previously treated with oral risperidone by J.K. Sliwa; C.A. Bossie; Y.W. Ma; A. Schreiner; J.T. Haskins; L. Alphs (S493).
P.3.c.062 The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia by A. Bose; D. Li; R. Migliore; P. Werner; G. Nemeth; I. Laszlovszky (S493-S494).
P.3.c.063 QoL, global functioning and social adaptation of schizophrenic subjects treated with long-acting risperidone by S. Tosic Golubovic; V.S. Sibinovic; V.S. Slavkovic; Z.O. Zikic; D.G. Gugleta (S494).
P.3.d.002 Cognitive impairment in patients with psychotic disorder diagnosis by L. Barbadillo; J. Carton; E. Ibarburu; L. Martin; M. Artola (S498-S499).
P.3.d.003 Effects of olanzapine on structure and function of brain tissue biomolecules during unpredictable chronic mild stress: an Fourier transform mid-infrared spectroscopic study by I. Komsuoglu; E. Gumuslu; S. Turker; O. Mutlu; F. Yildiz; F. Erden (S499).
P.3.d.013 Energetic metabolism, leptin are altered in rats submitted to chronic administration of olanzapine by A. Zugno; M. Barcelos; D. Fraga; L. Oliveira; L. Canever; R. Luca; G. Rezin; G. Scaini; E. Streck; J. Quevedo (S504-S505).
P.3.d.012 Action of clozapine depends on dopamine receptors presence on target cells -functional study by A. Faron-Gorecka; M. Kusmider; M. Gaska; K. Szafran; J. Solich; P. Palach; M. Dziedzicka-Wasylewska (S504).
P.3.d.014 Continuous paliperidone infusion versus repeated risperidone injections on cognition, prolactinemia and body weight in rats by L. Pani; S. Ruiu; G. Casu; C. Dessì; G. Pinna Spada; A.L. Deriu; G. Marchese (S505).
P.3.d.015 Treatment with memantine and imipramine induces changes in mitochondrial respiratory chain activity in the rat brain by D. Fraga; G. Réus; R. Stringari; G. Rezin; J. Daufenbach; E. Streck; J. Quevedo; A. Zugno (S505-S506).
P.3.d.016 Involvement of histaminergic receptors in the atypical antipsychotic profile of clozapine and N-desmethylclozapine by M. Humbert-Claude; E. Davenas; F. Gbahou; J.M. Arrang (S506).
P.3.d.011 Follow up screening for the metabolic syndrome in patients receiving antipsychotic treatment by L. Konstantinidou; T. Tsouvalas Athanasios; G. Georgiou Georgia; B. Birmpili Euaggelia-Maria (S503).
P.3.d.010 Antipsychotic drugs induce dopamine type 2 receptor mediated suppression of neuronal firing in the rat nucleus incertus by R. Rajkumar; M.N. Lee; G.S. Dawe (S502-S503).
P.3.d.005 Activity of phosphodiesterase 10A inhibitors in a novel animal model of negative symptoms of schizophrenia by B. Langen; D. Zschaber; H. Stange; T. Hage; N. Brandon; K. Marquis (S500-S501).
P.3.d.004 Influence of aripiprazole, risperidone, and amisulpride on PPI and P50-suppression in healthy males with low levels of gating by P.A. Csomor; F.X. Vollenweider (S499-S500).
P.3.d.007 Phencyclidine decreases tickled-induced 50-kHz calls in juvenile rats: a model for schizophrenia by D. Boulay; S. Ho-Van; O. Bergis; P. Avenet; G. Griebel (S501).
P.3.d.008 Massive creatin kinase and hepatic enzymes elevation due to quetiapine and valproic acid treatment by S. Erdogan; F.C. Celikel (S501-S502).
P.3.d.009 Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia by X. Langlois; A. Megens; H. Lavreysen; R. Wouters; L. Peeters; P. te Riele; H. Hendrickx; M. Mahieu; M. de Bruyn; G. Macdonald (S502).
P.3.c.002 Association between the alpha-2a-adrenergic receptor 1291 C/G polymorphism and the metabolic syndrome by A. Risselada; J. Vehof; R. Bruggeman; B. Wilffert; D. Cohen; A.F. Al Hadithy; J. Arends; H. Mulder (S458-S459).
P.3.c.001 Association between HTR2C polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study by A. Risselada; J. Vehof; R. Bruggeman; B. Wilffert; D. Cohen; A.F. Al Hadithy; J. Arends; H. Mulder (S458).
P.2.e.025 The risk of drug–drug interactions in the treatment of bipolar disorder by M. Vrabie; V. Marinescu (S416).
P.2.e.024 Cytokine profiles in bipolar affective disorder during acute episodes and in remission by A. Remlinger-Molenda; P. Wojciak; A. Kostrzewa; J. Karczewski; K. Wiktorowicz; J.K. Rybakowski (S415-S416).
P.2.e.026 Parenting and family planning characteristics among bipolar mothers compared to controls by D. Hupfeld Moreno; D. Bio; S. Petresco; D. Petresco; E. Gutt; R.A. Moreno (S416-S417).
P.2.e.027 Association of body mass index with depression and alexithymia by A. Karagöl; G. Ozcurumez; N. Taskintuna (S417).
P.2.f.001 Lithium treatment is not associated with functional or autoimmunitarian thyroideal abnormalities in bipolar disorder I by J. Cobo; E. Patró; J.D. Barbero; M. Pérez; C. Domènech; G. Severino; J.A. Monreal; O. Jiménez-Palop; F. Bleda; G. García-Parés (S418).
P.2.e.023 Switching from olanzapine to ziprasidone in patients with bipolar disorder: a 24-weeks, multi-center open-label trial by B. Yoon; W. Bahk; H. Lee; Y. Woo; Y. Kwon; A. Bae; M. KIm (S415).
P.2.e.022 Lamotrigine adjunctive therapy and possible sleep regulation in adult autism spectrum disorder: a case report by K. Ooga; Y. Abe; T. Okudaira; Y. Suzuki; Y. Ishikawa; Y. Furukawa; T. Kojima (S414-S415).
P.2.e.018 Frequency of mixed states in patients with a major depressive episode:the BRIDGE MIX study by G. Perugi; J. Angst; J.M. Azorin; C.L. Bowden; E. Vieta; A.H. Young (S412).
P.2.e.017 Life-time suicide attempts in acutely admitted inpatients with bipolar disorder by P.I. Finseth; G. Morken; U.F. Malt; O.A. Andreassen; A.E. Vaaler (S411-S412).
P.2.e.019 Thyroid function assessment in lithium-treated patients: preliminary results by A. Lagoudis; I. Iakovou; T. Christoforidis; C. Stergiokoglou; M. Syngelakis; G. Garyfallos; V. Bozikas (S412-S413).
P.2.e.020 Treatment with aripiprazole in Korean patients with acute manic or mixed episodes by Y.H. Ko; I.K. Jung; C.S. Han; J.W. Yang; M.S. Lee (S413).
P.2.e.021 Aripiprazole in combination with lamotrigine: long-term treatment of patients with bipolar I disorder (manic or mixed) by T. Ketter; B.X. Carlson; W. Sun; K. Timko; E. Vester-Blokland; R.D. McQuade; R. Sanchez; R. Owen (S413-S414).
P.2.f.002 Selective DNA methylation of BDNF promoter in bipolar disorder by C. D'Addario; B. Dell'Osso; D. Galimberti; E. Scarpini; B. Arosio; L. Bergamaschini; C. Fenoglio; S. Candeletti; P. Romualdi; A.C. Altamura (S418-S419).
P.2.f.003 No state-dependent alternation of immunological parameters, insulin, and leptin during bipolar depression by S.Y. Tsai; K.H. Chung; S.H. Huang (S419).
P.2.g.007 Standard antidepressant therapy vs association between amisulpride and antidepressant therapy in atypical depression by G. Grigorescu; A. Baloescu; D. Vasile; C. Tudor; O. Vasiliu; R. Grigorescu (S424-S425).
P.2.g.006 Vagus nerve stimulation in treatment-resistant depression (TRD): results from a systematic neuropsychiatric investigation by E. LaGarde; P. Lespérance; S. Patry; V.S. Tourjman; V. Desbeaumes; A. Bouthillier (S424).
P.2.g.008 Efficacy of milnacipran in patients with interferon-a2 induced depression by M. Zavoianu; A. Cantemir; C. Tudor; G. Grigorescu; D. Vasile (S425).
P.2.g.009 The incidence of psychiatric disorders in patients with hyperthyroidism by R. Chenderes; D.M. Podea; L. Stamoran; P.D. Nanu; C. Mila; L.E. Piros; N. Mihailescu (S425-S426).
P.2.g.010 Taurine levels in plasma before and after three ECT treatments by M. Samuelsson; G. Gerdin; M. Vrethem (S426).
P.2.g.005 Prescription of antipsychotics in inpatients with major depressive disorder in 2000 and 2007 – results from the AMSP pharmacovigilance project by K. Papageorgiou; A. Konstantinidis; R. Grohmann; A. Horvath; R. Engel; S. Kasper (S423).
P.2.g.004 Bupropion for adults with ADHD: meta-analysis of randomised, placebo-controlled trials by N. Maneeton; B. Maneeton; S. Srisurpanont (S422-S423).
P.2.f.005 Pharmacological treatment in bipolar I and II disorders by N. Varela Gómez; N. Ferrier; J. Mayoral-Van Son; T. Moreno Calle (S420).
P.2.f.004 Anti-estrogenic drugs do not reproduce the antimanic-like effect of tamoxifen in methylphenidate-induced hyperlocomotion by R. Andreatini; M. Pereira; B.J. Martynhak; I.P. Baretta; D. Correia (S419-S420).
P.2.g.001 Association of mood depression with inflammation and oxidative stress in peritoneal dialysis patients by S. Park; Y. Jung; J. Park; H. Shin; H. Rim (S421).
P.2.g.002 Sexual dysfunction in depressed subjects with enduring personality change (F62.0) taking mirtazapine by M. Stojakovic; S. Vukadinovic; B. Stojakovic; D. Trkulja; S. Medenica; N. Selman (S421-S422).
P.2.g.003 The effect of antipsychotic combination with antidepressants to reach remission in elderly depressive patients by M. Seo (S422).
P.2.e.016 Psychotic versus non-psychotic bipolar II disorder by A. Murru; L. Mazzarini; F. Colom; I. Pacchiarotti; A.M.A. Nivoli; C.M. Bonnin; G.D. Kotzalidis; E. Vieta (S411).
P.2.e.015 Clinical trials to clinical practice: retrospective analysis of 25 patients with bipolar mania treated with aripiprazole by T. Rana (S410-S411).
P.2.d.017 Effect of antidepressants on apoptosis of rat cortical neurons subjected to oxygen–glucose deprivation in vitro by A. Pudelko; E. Obuchowicz (S400).
P.2.d.016 Postweaning enriched environment and citalopram overcome memory deficits and anhedonia induced by maternal separation by Z. Zhang; S.S. Liu; J.J. Hui (S399-S400).
P.2.d.018 Analysis of the effects of chronic antidepressant treatment on neuronal plasticity in middle-aged rats by R. Guirado; S. Hernandez; S. Vidueira; J. Nacher (S400-S401).
P.2.d.019 Prefrontal oscillation associated with randomised, placebo-controlled treatment with agomelatine and psychotherapy by B. Loza; M. Polikowska; M. Szubert-Czarnocka; P. Bednarski; J. Grzesiewska; J. Kwasna; A. Mosiolek; I. Patejuk-Mazurek; P. Wnukiewicz; R. Wojcik (S401).
P.2.d.020 Serum VEGF during electroconvulsive therapy (ECT) in drug resistant depressed patients by A. Minelli; R. Zanardini; M. Abate; M. Bortolomasi; M. Gennarelli; L. Bocchio Chiavetto (S401-S402).
P.2.d.015 Adolescent escitalopram administration modifies neurochemical alterations in hippocampus of maternally separated rats by Z.J. Zhang; J.J. Hui; S.S. Liu; G.J. Xi; G.J. Teng; K.C. Chan; G.P. Reynolds (S399).
P.2.d.014 Changes in genes and proteins level of Nr4a1, Egr1 and Id1 in rat brain after antidepressant treatment by M. Gaska; M. Kusmider; J. Solich; A. Faron-Górecka; M. Dziedzica-Wasylewska (S398-S399).
P.2.d.010 Effects of trazodone and paroxetine on expression of hippocampal AMPA receptors and fEPSPs at CA3/CA1 synapses in rats by E. Gerace; G. Stocca; E. Zianni; M. Magnani; L. Polenzani; L. Olivieri; D. Pellegrini-Giampietro; R. Corradetti (S396).
P.2.d.009 The role of GIRK channels on the behavioural effects induced by the antidepressant reboxetine by M. Torrecilla; I. Fernandéz-Aedo; L. Ugedo (S395).
P.2.d.011 Low dose pipamperone, enhancing antidepressant effect of citalopram, occupies 5HT2A 50–60% leaving D2 nearly drug free by E. Buntinx; K. Bol; P. van den Berg; E. Spaans; L. Haazen (S396-S397).
P.2.d.012 Role of 5-HT1A receptor on extracellular 5-HT increase induced by trazodone in the rat prefrontal cortex by B. Garrone; S. De Santi; D. D'Amico; G. Mangano; L. Olivieri; M. Magnani; L. Polenzani; A. Guglielmotti (S397).
P.2.d.013 Differential noradrenergic and serotonergic modulation of the neural correlates of the processing of emotional pictures by A.B. Bruehl; T. Kaffenberger; L. Jäncke; U. Herwig (S397-S398).
P.2.e.001 Patterns of mood stabiliser drug prescription for Iranian patients with diagnosis of bipolar mood disorder by G. Ahmadzadeh; A. Farhat (S402).
P.2.e.002 Relationship between clinical characteristics, objective psychopathology and subjective deficits of bipolar disorder by S. Joe; D. Kwon; S. Cho (S402-S403).
P.2.e.011 Correlation between clinical symptoms, serum uric acid level, and beta wave of EEG in patients with bipolar disorder by Y. Lee; D. Han; D. Noh; S. Kim; C. Na (S408).
P.2.e.010 Effectiveness of quetiapine versus bupropion as adjunctive treatment in bipolar depression by K.J. Lee; H. Kim (S407-S408).
P.2.e.012 Use of traditional and alternative therapies in people who suffer bipolar disorders: impact on compliance by S. Strejilevich; M. Scapola; D. Martino; M. Sarmiento; L. Gil; C. Gomez Restrepo (S408-S409).
P.2.e.013 Effectiveness of quetiapine in bipolar depression patients: a multi-centre, prospective, open-label, observational study by J. Jeong; W.M. Bahk; Y.S. Woo; K.J. Min; D.I. Jon; B.H. Yoon (S409).
P.2.e.014 Combined antidepressant and quetiapine therapy in bipolar I mixed – one-year follow up by G. Callista; E. Daneluzzo (S409-S410).
P.2.e.009 Gender differences in bipolar disorders by A.M.A. Nivoli; F. Colom; A. Rosa R; D. Popovic; I. Pacchiarotti; A. Murru; E. Vieta (S406-S407).
P.2.e.008 Initial antidepressant monotherapy in bipolar depression is associated with more depressive relapses and switches by M. Valentí; I. Pacchiarotti; A.M.A. Nivoli; A. Murru; F. Colom; E. Vieta (S406).
P.2.e.004 Neuropsychological and psychosocial impairment in euthymic bipolar patients by E. Mora; I. Forcada; M. Mur; M.J. Portella; N. Vidal; J. Pifarre; E. Vieta (S404).
P.2.e.003 Cys145Ser change in the AKR1C4 gene associated with manic irritability and lower progesterone in male bipolar patients by A.G.M. Johansson; P. Nikamo; M. Landen (S403).
P.2.e.005 Mood stabilisers and atypical antipsychotics in the long-term treatment of bipolar disorder by A.C. Altamura; M. Buoli; R.A. Paoli; D. Primavera (S404-S405).
P.2.e.006 Can we distinguish bipolar from unipolar depression: preliminary results by L.G. Hranov; V. Simov; G. Hranov (S405).
P.2.e.007 Outcome of bipolar illness and comorbid personality disorder by O. Garcia López; P. Fernandez-Argüelles; N. Casas; M. Camacho; J.M. Garcia (S405-S406).
P.2.g.011 Implications of oxidative stress in patients with depressive disorder and insomnia by R. Vitalaru; M. Padurariu; A. Cantemir; A. Ciobica; C. Stefanescu (S426-S427).
P.2.h.001 Polymorphisms in the BDNF gene are associated with antidepressant treatment response by J. Hennings; M. Kohli; A. Heck; D. Roeske; T. Brückl; T. Klengel; A. Menke; B. Müller-Myhsok; M. Ising; F. Holsboer; S. Lucae (S427-S428).
P.3.a.033 Electrophysiological measures and clinical scales in schizophrenia and bipolar disorder by N. Domján; G. Csifcsák; I. Szendi; Z. Janka (S447-S448).
P.3.a.032 Sexual dysfunction in a Tunisian sample of drug free schizophrenic patients: a case-control-study by Y. El Kissi; S. Gaabout; M. Laaroussi; M. Ayachi; J. Nakhli; B. Ben Hadj Ali (S447).
P.3.a.034 Elaboration on the association between immigration and schizophrenia: a population based national study by N. Werbeloff; S.Z. Levine; J. Rabinowitz (S448).
P.3.a.035 Cognitive responce as a predictor of repetitive transcranial magnetic stimulation (rTMS) efficacy in schizophrenia by N. Maslenikov; E.E. Tsukarzi; S.N. Mosolov (S448-S449).
P.3.a.036 Cognitive impairment: response to a depot antipsychotic in a South African first-episode psychosis cohort by R. Schoeman; P.P. Oosthuizen (S449).
P.3.a.031 Service utilisation of schizophrenic patients treated with long-acting injectable risperidone in Taiwan by H. Chang; K. Su; P. McCropne (S446-S447).
P.3.a.030 Deformities caused by stable body posture in two cases with chronic psychotic disorder by M. Hacioglu; E. Ugurlu; E. Yildirim; S. Erek; O. Saatcioglu (S446).
P.3.a.026 Safety, tolerability and D2 occupancy of the fast dissociating D2 antagonist JNJ-37822681 in healthy subjects by M. Schmidt; P. de Boer; E. Mannaert; T. Iersel; L. van Nueten (S444).
P.3.a.025 Metabolic syndrome in inpatients with serious mental illness by P. Ntounas; I. Vlachos; R. Psaras; C. Tsopelas; I. Sovolakis; E. Gkeka; M. Dimitraka; E. Siouti; C. Touloumis (S443).
P.3.a.027 Prediction of un-planned readmission to hospital for patients with schizophrenia – a cohort-study of 277 patients by R. Kroken; L.S. Mellesdal; H.A. Jørgensen; T. Wentzel-Larsen; E. Johnsen (S444-S445).
P.3.a.028 Gender differences in suicidal behaviour of patients with depressive disorders by N.O. Maruta; L.T. Snovida (S445).
P.3.a.029 Acute and transient psychosis: focus on clinical features and stressful life events before the first episode by E. Rancans; M. Rusaka (S445-S446).
P.3.a.037 Hyperactivation of inflammatory response in depressed patients with psychomotor retardation by G. Camardese; B. Leone; B. Mattioli; G. Pizi; P. Bria (S449-S450).
P.3.a.038 Cannabis-induced psychosis: new entity? by Z. Makkos; L. Fejes; G. Inczedy-Farkas; A. Kassai-Farkas; J. Lazary (S450-S451).
P.3.b.007 Epistasis between variations located in TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotics by T. Jun; C. Pae; H.R. Wang; A. Serretti (S455-S456).
P.3.b.006 Evidence of reduced tiiodothyronine in refractory schizophrenics under clozapine: cause or effect? by P. Belmonte-de-Abreu; C.S. Gama; M.I. Lobato; H. Brentani; R. Massuda; J.A. Palha (S455).
P.3.b.008 Postsynaptic density-95/93 in rat hippocampus affected by NR1/NR2 antisense oligodeoxynucleotide by M. Vrajova; V. Bubeníková-Valeová; M. Fujáková; J. Klaschka (S456).
P.3.b.009 Interaction analysis of apolipoprotein D and dopamine D2 receptor gene variants in schizophrenia by P.Z. Álmos; S. Horváth; A. Juhász; Z. Janka (S456-S457).
P.3.b.010 Examination of nociceptive behaviour and stress reactivity in susceptibility gene mutant models of schizophrenia by C. O'Tuathaigh; J. Walsh; O. Tighe; M. Karayiorgou; J. Gogos; R. Harvey; D. Lai; J.L. Waddington (S457-S458).
P.3.b.005 Proton magnetic resonance spectroscopy measures predict a short-time symptomatic outcome in chronic schizophrenia by A. Szulc; B. Galinska; E. Tarasow; B. Kubas; B. Konarzewska; R. Poplawska; N. Waszkiewicz (S454-S455).
P.3.b.004 Advanced paternal age generates higher risk for schizophrenia than for alcohol addiction by B.I. Dragomir; C.N. Marginean; M. Valcu; L. Fodoreanu (S454).
P.3.a.040 Reasons for admission of psychotic patients to psychiatric emergency services by R. Florea; H. Ho Quoc; P.H. Courtet (S451-S452).
P.3.a.039 Prescribing behaviour of psychiatrists: data from the clinical analysis of the treatment of schizophrenia (CATS) project by N. Bergemann; P. Parzer; F. Rommel; M. Franz; M. Lautenschlager; J. Kammerer-Ciernioch; G. Schindler; P. Wallenfels; M. Weisbrod; M. Deuschle (S451).
P.3.b.001 Seasonality of serum melatonin concentrations in paranoid schizophrenic inpatients by E. Díaz Mesa; A. Morer Fumero; P. Abreu-González; A. Jiménez-Sosa; M. Henry; L. Fernández-López; A. Intxausti; R. Gracia-Marco (S452).
P.3.b.002 Peculiarities of psychotic migrant Romanian patients by A.M. Vremaroiu; L. Fodoreanu; I. Miclutia; C. Popescu (S453).
P.3.b.003 Mapping brain regions in which deep brain stimulation affects schizophrenia-like behaviour in rats – a pilot study by J. Klein; C. Eberhardt; A. Männer; J. Baldassarri; R. Morgenstern; C. Winter (S453).
P.3.a.024 Risk for coronary heart disease in inpatients with serious mental illness by P. Ntounas; C. Tsopelas; I. Vlachos; I. Sovolakis; E. Gkeka; R. Psaras; E. Siouti; C. Touloumis (S442-S443).
P.3.a.023 The relationship of the clinical characteristics of Korean schizophrenia with serum homocysteine and folate levels by T.H. Kim; S.W. Moon (S442).
P.3.a.006 Attitudes concerning depot medication in German general population – a representative telephone survey by J. Cordes; S. Arnau; K. Hoppe; J. Thünker; I. Wittib (S432-S433).
P.3.a.005 The impact of cannabis use on cognitive functioning in schizophrenia: a meta-analysis of existing findings and new data by M. Yücel; E. Bora; D.I. Lubman; N. Solowij; W.J. Brewer; S. Cotton; P. Conus; A. Fornito; P.D. McGorry; C. Pantelis (S432).
P.3.a.007 Subjective well-being in schizophrenia is inversely correlated with the presence and severity of depressive symptoms by J. Sanjuan; J.M. Haro; J. Maurino; T. Diez; J. Ballesteros (S433-S434).
P.3.a.008 Factors affecting treatment discontinuation and treatment outcome in patients with schizophrenia: a 10-year follow-up study by H.J. Choi; S.H. Jung; C.E. Kim (S434).
P.3.a.009 Negative symptoms: neglected but important targets for treatment by R. Hunter; S. Barry (S434-S435).
P.3.a.004 Clinical variables, cognitive assessment and positron emission tomography (PET) in schizophrenic inpatients by M. Buoli; E. Caletti; M. Serati; R.A. Paoli; B. Dell'Osso; A.C. Altamura (S431-S432).
P.3.a.003 Comorbidity of dandy walker complex malformations and schizophrenia, case series by E. Yildizhan; G. Özgen; A. Türkcan; Z. Öztürk (S431).
P.2.h.003 Suicide attempts in a mental health unit of Galicia by B. Pórtela Traba; M. Pérez García; A. Mozos Ansorena (S428-S429).
P.2.h.002 Chronic stress induces changes in neuronal plasticity and inhibitory neurotransmission in the amygdala of adult mice by J. Gilabert-Juan; E. Castillo-Gomez; M.D. Moltó; J. Nàcher (S428).
P.2.h.004 Antidepressant and antipsychotic-like effects of GABA-B receptor ligands in mGlu7 deficient mice by J.M. Wieronska; P. Branski; T. Lech; M. Marciniak; A. Pilc (S429).
P.3.a.001 Evaluation of the effect of aripiprazole on quality of life in patients with schizophrenia by C. Bervoets; E. Constant; B. Sabbe; M. Morrens; K. Vansteelandt; A. De Patoul; D. Pitzi; V. Halkin; J.Y. Loze; J. Peuskens (S429-S430).
P.3.a.002 Evaluation of theta burst stimulation on the resistant auditory hallucinations: a pilot study by D. Sidhoumi; S. Braha; N. Bouaziz; R. Benadhira; D. Januel (S430-S431).
P.3.a.010 Visual processing abnormalities as biomarker for schizophrenia: an EEG study in the schizophrenia spectrum by I. Koychev; W. El-Deredy; C. Haenschel; J.F.W. Deakin (S435).
P.3.a.011 Descriptive study of suicidal behaviour in delusional disorder by M. Pérez García; A. Mozos Ansorena; B. Portela Traba; M. Páramo Fernández; J. Brenlla González (S435-S436).
P.3.a.019 Discontinuity of treatment with antipsychotics and neurostructural changes in an animal model by D. Marinescu; L. Mogoanta; T. Udristoiu (S440).
P.3.a.018 A role for structural equation modeling in subtyping schizophrenia in an African population by L. Koen; D.J.H. Niehaus; R.A. Emsley; E. Jordaan (S439-S440).
P.3.a.020 Weight gain as a marker of evolution to patients with multiple episodes schizophrenia and depressive symptoms by I. Marinescu; D. Marinescu; M. Pirlog; A. Chimorgiachis (S440-S441).
P.3.a.021 Prepulse inhibition in patients with first-episode of schizophrenia: differences related to cannabis abuse disorder by I. Morales; G. Rubio; R. Jurado; M. Caballero; I. Martínez-Gras; G. Ponce; M.A. Jiménez-Arriero; T. Palomo (S441).
P.3.a.022 QoL of schizophrenic inpatients treated with risperidone or haloperidol by D. Vukic (S441-S442).
P.3.a.017 Global functioning amongst patients at a psychiatric emergency service: preliminary results by N. Manzanares; A. García-Villarrubia; S. Arranz; O. González; A. Sáenz; J. Peña (S439).
P.3.a.016 Importance of demographic factors and neuropsychological functioning in schizophrenic patients treated with olanzapine by K. Krysta; A. Borkowska; M. Bielinski (S438-S439).
P.3.a.012 Alteration in resting state brain connectivity in subjects with high genetic risk of psychosis by J.H. Jang; W.H. Jung; E. Kim; G. Shim; H.Y. Park; D.H. Kang; C.H. Choi; J.S. Kwon (S436).
P.3.a.013 Fatigue, sleepiness and sleep quality in psychotic disorders by C. Widakowich; D. Neu; V. Nagant; G. Steegen; P. Verbanck (S436-S437).
P.3.a.014 Factors influencing patients' experience of stigma in the outpatients with schizophrenia by C. Kim (S437).
P.3.a.015 Study of the efficacy and safety of risperidone long acting injection in elderly schizophrenia patients by Y. Inoue; H. Suzuki; M. Ootomo; S. Takeda; Y. Kawaguchi; K. Gen (S438).
P.4.a.006 Differences in duration of untreated illness in patients with anxiety disorders by B. Dell'Osso; M. Buoli; L. Lietti; L. Oldani; G. Camuri; B. Benatti; E. Catenacci; C. Bressi; A.C. Altamura (S523-S524).
P.4.a.007 Verbal memory deficits in patients with posttraumatic stress disorder with and without major depression by M.J. Nijdam; M. Olff (S524).
P.6.f.004 Effect of toluene chronic inhalation on the process of learning in adult and adolescent rats by M. Zhvania; T.Z. Bikashvili; N.J. Japaridze; L. Gelazonia; L. Chilachava; V. Okuneva (S610).
P.6.f.003 Repeated administration of modafinil induces behavioural sensitisation in mice by K. Slais; A. Machalova; D. Vrskova; A. Sulcova (S609).
P.7.a.001 Clinical characteristics of bipolar disorder in children and adolescents in Egypt by M. Abd El-hay; A. Badawy; H. El Sawy (S610-S611).
P.7.a.002 A controlled family study of children with DSM-IV bipolar-I disorder by J. Biederman; J. Wozniak; S. Faraone; E. Mick (S611).
P.7.a.003 The long term course of pediatric bipolar disorder: a five year longitudinal follow up study by J. Biederman; J. Wozniak (S611-S612).
P.6.f.002 Hypericum perforatum, nicotine patches and combination hypericum perforatum/nicotine patches for smoking cessation by M. Kras; C. Stough; A. Scholey; C. Kure; D. Camfield (S608-S609).
P.6.f.001 Diminished error processing in smokers during smoking cue exposure: an ERP study by M. Luijten; I.H.A. Franken (S608).
P.6.e.003 Acute psychotic disorder due to the use of ethnobotanical substances by M. Ladea; M. Lepadat; M. Bran; M.C. Sarpe (S606).
P.6.e.002 The effect of abstinence from internet video games on working memory in students with excessive internet game playing by C. Na; S.M. Kim; D.H. Han; D.H. Noh; Y.S. Lee (S605-S606).
P.6.e.004 The effect of smoking cessation on trait anger and personality trait in schizophrenia by H. Lee; S. Hahn; B. Ham; J. Paik; M. Lee (S606-S607).
P.6.e.005 Suicide and dual diagnosis by R. Martinez; G. Mateu; L. Díaz; L. Morro; R. Rodríguez; D. Martínez; A. Merino; M. Torrens (S607).
P.6.e.006 Cue reactivity in pathological gamblers and smokers: an fMRI study of behavioural and substance related addictions by A.E. Goudriaan; M.B. de Ruiter; J. Oosterlaan; W. van den Brink; D.J. Veltman (S607-S608).
P.7.a.004 Psychiatric outcomes of girls with ADHD grown up: a controlled 11-year follow-up study by J. Biederman; C. Petty; M. Monuteaux; S. Faraone (S612-S613).
P.7.a.005 Antipsychotic metabolic effects in bipolar youth: comparison with other psychotic and non-psychotic diagnoses by M. Rapado-Castro; C. Moreno; J. Merchan-Naranjo; M. Álvarez; I. Baeza; J.A. Alda; C. Martínez-Cantarero; B. Sánchez; E. de la Serna; C. Arango (S613).
P.7.b.001 Influence of psychopathology and neurocognitive function on behavioural symptoms in children with ADHD by J.S. Kim; H.M. Sung; J.B. Lee; K.H. Lee; S.K. Sakong (S618-S619).
P.7.a.013 Interest of a mobile emergency response team in adolescents' mental health by G. Shadili; E. Dauly; G. Noël (S618).
P.7.b.002 “Quod me nutrit, me destruit” – the pro-anorexia phenomenon: research on the Polish pro-ana virtual community by M. Stochel; W. Losiak; M. Janas-Kozik (S619).
P.7.b.003 Association study of the serotonin 1A receptor gene and tryptophan hydroxylase 2 gene in ADHD by Y. Kwon; S. Shim; H. Jung (S619-S620).
P.7.b.004 Association between dopamine receptor D4 gene polymorphism and drug response in Tourette syndrome by K. Lee; K.C. Paik; M.H. Lim (S620).
P.7.a.012 Dyskinesia in naïve children and adolescents treated with olanzapine, risperidone and quetiapine: three months follow up by J. Merchán-Naranjo; M. García-Amador; M. Leiva-Resino; C. Llorente; C. Tapia-Casellas; M. Giráldez; D. Fraguas; C. Arango (S617).
P.7.a.011 Childhood ADHD in Europe: a comparison of patient and physician profiles across countries by R. Sasane; D. Mitra; P. Hodgkins; K.L. Davis (S616-S617).
P.7.a.007 Intelligence and neurocognitive functioning by Korean Personality Inventory for Children (KPI-C), profile type in children with ADHD by J.S. Kim; B.H. Koo; J.K. Sakong; S.H. Song (S614-S615).
P.7.a.006 Impairment of concept formation ability in children with ADHD: comparisons between lower grades and higher grades by J.S. Kim; H.M. Sung; J.B. Lee; K.H. Lee; J.K. Sakong (S613-S614).
P.7.a.008 Treatment compliance in children and adolescents initiated on ADHD medication in clinical practice (COMPLY) by P. Wehmeier; D. Quail; R.W. Dittmann; T. Banaschewski (S615).
P.7.a.009 Different levels of salivary steroids in autistic and healthy children by M.D. Majewska; M. Hill; E. Urbanowicz; P. Rok-Bojko; I. Namyslowska; P. Mierzejewski (S615-S616).
P.7.a.010 Comorbidity in patients with attention deficit hyperactivity disorder in psychiatric population in prison by O. Sanz-Garcia; R.M. Dueñas; V. Burges; A. Muro; F. Perez (S616).
P.6.e.001 Cognitive flexibility in pathological gambling and alcohol dependence: an fMRI study by R.J. van Holst; A.E. Goudriaan; D.J. Veltman; W. van den Brink (S605).
P.6.d.028 Dysfunctional response inhibition correlates with reduced gray matter in the inferior frontal gyrus of cocaine abusers by L. Moreno; E.A. Stamatakis; M.J. Fernández-Serrano; E. Delgado-Rico; M. Pérez-García; A. Verdejo-García (S604).
P.6.d.010 Changes in GABAergic expression of habenula and hippocampal formation in mouse administered with amphetamine by L.T. Li; T.W. Tien; Y.H. Yang; H.S. Yin (S593-S594).
P.6.d.009 Tobacco and suicidal ideation by M. Vidal Millares; M.C. Armas Barbazán; M.C. García Mahía; P. de Usabel Guzmán; L. Vigo Santamariña; M.J. Mota Rodriguez; A. Pampin Alfonso (S593).
P.6.d.011 Acute, chronic and withdrawal effects of cocaine on apoptotic signaling in rat brain by M. Alvaro-Bartolomé; J.A. García-Sevilla (S594).
P.6.d.012 Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by cannabinoid withdrawal by A. Aracil; P. Almela; J. Manzanares (S594-S595).
P.6.d.013 Cocaine fails to induce sensitisation to motor responses in transgenic mice overexpressing cannabinoid CB2 receptors by A. Aracil; J. Manzanares (S595).
P.6.d.008 Association between NrCAM gene variants, working memory and cognition in methamphetamine abuse by B. Lee; Y. Kim; D. Kwon; Y. Chung; J. Park; S. Kim; C. Kang; J. Kim; Y. Lee (S592-S593).
P.6.d.007 Attentional bias to smoking-related cues: a comparison of daily smokers, social smokers and non-smokers by E.L. Mullings; M.R. Munafò (S592).
P.6.d.003 Blockade of amygdalar CRF and dopamine receptors diminishes the reinforcing effects of opiates and opioids by P. Shabanov; A. Lebedev; A. Lyubimov; V. Kornilov (S589-S590).
P.6.d.002 Expression of NMDA receptor subunits in human peripheral blood lymphocytes in opioid addiction by R. Roozafzoon; A. Goodarzi; N. Vousooghi; P. Yaghmaei; M. Sedaghati; M.R. Zarrindast (S589).
P.6.d.004 Transient inactivation of nucleus accumbens reduces morphine place preference in rats by H. Sahraei; H. Alieig; M. Ardehari (S590).
P.6.d.005 Evaluation of the role of central adenosine A1 and A2a receptors in the development of tolerance to morphine analgesia in rats by M. Charkhpour; A. Parvizpur; F. Ebrahimi; P. Talebi; H. Samadi; Z. Namjo (S590-S591).
P.6.d.006 Effects of nicotinised and denicotinised cigarette smoking on response to 7.5% carbon dioxide anxiety challenge by A.S. Attwood; J.E. Bailey; D.J. Nutt; A.F. Ataya; M.R. Munafò (S591).
P.6.d.014 The severity of morphine abstinence correlates with brain FADD phosphorylation: interaction with α2-adrenoceptors by A. Ramos-Miguel; A. Miralles; J.A. García-Sevilla (S596).
P.6.d.015 Altered norepinephrinergic and parvalbumin expression in hippocampal formation of mouse deficient in monoamine oxidase B by H. Yin; T. Tien; J. Wang; J. Shih; K. Chen (S596-S597).
P.6.d.024 Serotonergic challenge of memory functions in MDMA users by K. Preller; N. Dörig; F. Hasler; F.X. Vollenweider; B.B. Quednow (S602).
P.6.d.023 Effects of different schedules of neuroleptic treatment on mesolimbic and nigrostriatal dopaminergic supersensitivity by R. Frussa-Filho; J. Palermo-Neto (S601).
P.6.d.025 Reduced feed-back related negativity is associated with reinforcement-learning deficits in cocaine dependent patients by M. Kometer; S. Meier; B.B. Quednow; F.X. Vollenweider (S602-S603).
P.6.d.026 Impaired color vision in recreational stimulant users by L. Hulka; M. Wagner; K.U. Kühn; W. Maier; B.B. Quednow (S603).
P.6.d.027 Magnesium as modulator of NMDA receptors in morphine-induced behavioural sensitisation by D. Chelarescu; C. Filip; M. Cuciureanu; O.C. Chelarescu; C. Ghiciuc (S603-S604).
P.6.d.022 The role of serotonin and dopamine systems in the action of the psychedelic 4-bromo-2,5-dimethoxyphenylethylamine (2C-B) by T. Palenicek; M. Fujakova; I. Gorman; L. Rambousek; V. Bubenikova-Valesova; J. Horacek (S600-S601).
P.6.d.021 Cannabinoid CB2 receptor antagonist prevents cannabidiol-induced decrease in body weight gains in rats by B. Ignatowska-Jankowska; M.M. Jankowski; W. Glac; A.H. Swiergiel (S600).
P.6.d.017 Tiagabine prevents changes in alpha(1)-adrenoceptor subtypes induced by cocaine sensitization: immunohistochemical study by J. Kusmierczyk; G. Kreiner; A. Zelek-Molik; M. Kowalska; I. Nalepa (S597-S598).
P.6.d.016 Impulsive choice predicts resistance to extinction and vulnerability to reinstatement of cocaine seeking by N. Broos; A.N.M. Schoffelmeer; L. Diergaarde; T. Pattij; T.J. De Vries (S597).
P.6.d.018 Cocaine, morphine and the cannabinoid win55212 depress neuronal activity in the rostromedial tegmental nucleus by S. Lecca; A. Luchicchi; S. Carta; M. Melis; A.L. Muntoni; M. Pistis (S598).
P.6.d.019 Peroxisome proliferator activated receptors type alpha modulate nicotine effects in the rat ventral tegmental area by A. Luchicchi; S. Lecca; S. Carta; M. Pistis (S598-S599).
P.6.d.020 Dose-dependent effects of repeated intravenous cocaine on CD4:CD8 lymphocyte ratio in peripheral blood of rats by M.M. Jankowski; B. Ignatowska-Jankowska; W. Glac; A.H. Swiergiel (S599-S600).
P.7.c.001 Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses by M. Hrdlicka; I. Zedkova; M. Blatny; T. Urbanek (S620-S621).
P.7.c.002 Efficacy of risperidone on the core symptoms of autistic disorder by D. Kolar (S621).
C.05.03 Treating the symptoms: what matters to the patient? by R. Kahn (S641).
C.05.02 The patient journey: acute mania through to remission by A. Young (S640-S641).
C.07.01 Innovative antidepressant treatment targets by B.E. Leonard (S641-S642).
C.07.02 Pharmacogenetics of antidepressants by J. Mendlewicz (S642).
C.07.03 Clock genes at the heart of depression by D.J. Kennaway (S642).
C.05.01 Schizophrenia: positive and negative symptom relief by P. Falkai (S640).
C.04.02 The comorbidity of generalised anxiety disorder and depression: conceptualisation and options for therapy by D. Stein (S639-S640).
C.03.01 The importance of recognising organic causes of psychoses by P. Santosh (S638).
C.01.03 Long-term management of depression: what are the treatment options? by K. Demyttenaere (S638).
C.03.03 Clinical picture of an organic psychosis: Niemann-Pick type C by H.H. Klunemann (S638-S639).
C.03.04 Changing the disease course: disease-modifying treatment for Niemann-Pick type C by F. Sedel (S639).
C.04.01 Treatments for generalised anxiety disorder: mechanism of action and clinical effect by D. Nutt (S639).
C.08.01 Addressing the adherence challenge in psychosis by J.M. Olivares (S642-S643).
C.12.03 Keeping the patient well: a new option to improve remission rate by P.M. Llorca (S646-S647).
C.12.02 Earlier symptom relief means better outcome of depression by R. Lam (S646).
C.12.04 Clinical experience with agomelatine in depressed patients by G. Goodwin (S647).
Author Index (S649-S668).
Keyword Index (S669-S675).
C.12.0l Restoring circadian rhythms: a new way to successfully manage depression by P. Gorwood (S646).
C.11.03 The bipolar environment: the need for effective treatment in bipolar disorder by H. Akiskal (S645).
C.10.01 Gene–environment interactions – role in depressive and anxiety disorders by A. Tyrka (S644).
C.08.04 Moving beyond efficacy in schizophrenia: what do current antipsychotics offer our patients with schizophrenia? by A. Schreiner (S643).
C.10.02 Late-life depression – do we diagnose and treat correctly? by E. Topinková (S644).
C.10.03 Major depressive disorder – are there still unsolved questions? by T.E. Schläpfer (S644-S645).
C.11.02 Using pharmacological insights to inform real-life decision making – part 2 by A. Fagiolini; W. Pitchot (S645).
C.01.02 Disease severity and treatment-resistance: unraveling the treatment options in depression by M. Thase (S637).
C.01.01 Bipolar depression: managing hard to treat symptoms by L. Yatham (S637).
P.7.c.011 Efficacy of antiepileptic drugs in children and adolescents with cerebral palsy by P. Ignjatovic; N. Jovic (S626-S627).
P.7.c.010 The cost effectiveness of aripiprazole for the treatment of adolescents with schizophrenia by L. Pericleous; E. Dudley; M. Lebmeier; A. Bentley; R. McAllister (S626).
P.7.d.001 Cognitive and clinical responses among first episode and chronic schizophrenic patients before and after L'Aquila earthquake by R. Pollice; V. Bianchini; L. Verni; M. Mazza; R. Roncone; M. Casacchia (S627).
P.7.d.002 Psychopathology, quality of life, and parental help-seeking behaviours in Korean children with short stature by J. Hwang; B. Lee; J. Seo; S. Lee (S627-S628).
P.7.d.003 A clinical usefulness of Korean version of strengths and difficulties questionnaire (SDQ-Kr) by J. Ahn; S. Park; J. Shin (S628).
P.7.c.009 Management of ADHD among children in Europe: a comparison of practice patterns across countries by D. Mitra; R. Sasane; P. Hodgkins; K.L. Davis (S625-S626).
P.7.c.008 The effect of prolonged-release methylphenidate on the sleep of children with attention-deficit/hyperactivity disorders by I. Chung; C.H. Han; H.W. Kim; S.C. Cho (S624-S625).
P.7.c.004 Changes in parental depressive mood and quality of life following treatment of ADHD children by J. Hwang; Y. Kim; B. Kim; B. Kim; S. Cho (S622-S623).
P.7.c.003 One-year follow up of change in functioning in naïve ADHD patients treated with atomoxetine or other standard treatment by R. Escobar; D. Quail; K. De Bruyckere; M. Casillas; P. Berquin; K. Puvanendran; J. Fuentes (S622).
P.7.c.005 How do we treat patients with undiagnosed attention deficit hyperactivity disorder? Psychiatric population study in prison by O. Sanz-Garcia; R.m. Dueñas; N. Domenech; R. Ramón; A. Muro; F. Perez (S623).
P.7.c.006 Issues and opportunities in cognitive psychopharmacology trials in children by K.A. Wesnes; H. Brooker (S623-S624).
P.7.c.007 Self-injury among Croatian adolescents: important risk factors by K. Dodig-Curkovic; M. Curkovic; D. Degmecic; P. Filakovic (S624).
P.7.e.001 Characteristics of executive function in children with combined type of attention deficit hyperactivity disorder by E.J. Kim; K.W. Yun (S629).
P.7.e.002 European professionals' attitudes and practices in the management of ADHD by M. Fitzgerald; F. McNicholas; L. Henson (S629-S630).
P.8.a.009 Hospitalisation of immigrant patients in a psychiatric sector of a Greek general hospital by M. Anagnostopoulou; A. Karkanias; A. Tselebis; A. Christodoulaki; A. Karakostas; D. Bratis; G. Moussas (S634).
P.8.a.008 Agressivity management in mobile emergency unit by P. Alvaro; A. Martínez; M. Nascimento; D. Córcoles; A. Malagón; F. Portillo; J. Ginés; M. Bellsolà; L.M. Martín; A. Bulbena (S633-S634).
P.8.a.010 Coercion in psychiatric care: can paternalism justify coercion? by H. Lee; S. Kim; M. Seo; M. Rhee (S634-S635).
P.8.a.011 Psychiatric symptoms among end stage renal disease patients: prevalence and risk factors by D. Radwan; K. Abou Seif; D. Sany; A. Ayed (S635).
P.8.a.012 25-hydroxyvitamin D blood levels in recently admitted psychiatric inpatients by J.J. Mast; K.M. Koorengevel; N.J. van Beveren (S635-S636).
P.8.a.007 Examining patient validity for clinical trials: a post-hoc analysis of placebo responders by L. Brownstein; H. Hassman; S. Haley (S633).
P.8.a.006 CSF 3-methoxy-4-hydroxyphenylglycol (MHPG) and dexamethasone test as predictors of suicide risk by J. Jokinen; J. Ouda; P. Nordström (S632-S633).
P.8.a.002 A one-year follow-up study on suicide attempters: profile of persons who committed suicide by F. Vasquez; Y. Nicolas; S. Falconí; V. Vite (S630-S631).
P.8.a.001 Dynamics of psycho-vegetative disorders and oncomarkers in chemo-radiotherapy cancer patients exposed to blue light by G. Markarov; S. Shvarkov; J. Fedotova (S630).
P.8.a.003 Polypharmacy among psychiatric outpatients in Kuwait by S. Eid; N. Alsafar; S. Alqatan; H. Metwalle (S631).
P.8.a.004 Bridge the gap between primary and psychiatric secondary care by A. Shoka; H. Armson (S631-S632).
P.8.a.005 Diagnosis of mental illness by psychiatrists through paintings by C. Rochegude; R. Schwan (S632).
P.6.d.001 Effect of ORL1 receptor activation on opioid- and psychostimulant-induced conditioned place preference in rats by K. Rutten; J. De Vry; W. Bruckmann; T.M. Tzschentke (S588).
P.6.c.011 A case of unusual severe and prolonged gammabutyrolactone (GBL) withdrawal, treated successfully with valproate by J. Wolf (S587-S588).
P.4.d.002 Electroencephalographic activity defines the temporal-window for pentylenetetrazole role as an unconditioned stimulus by J. Cavalli; A.A. Hoeller; M. Duzzioni; T.C.M. De-Lima; L.J. Bertoglio; A.P. Carobrez (S545-S546).
P.4.d.001 Influence of peptide bioregulator on hormones in therapy of patients with organic disorders by L. Ryadovaya; S. Ivanova; V. Semke (S545).
P.4.e.001 Lost productivity time among workers with panic disorder and the improvement after 12 weeks of pharmacotherapy by J. Woo; W. Kim (S546-S547).
P.4.e.002 Clinical differences between PTSD and adjustment disorders in adolescent by M. Lee; J. Lee; S. Park (S547).
P.4.e.003 Clomipramine and quetiapine augmentation for obsessive compulsive disorder compared to sustained fluoxetine treatment by J.B. Diniz; C.A.B. Pereira; E.C. Miguel; R.G. Shavitt (S547-S548).
P.4.c.006 Day 3&7 jitteriness symptoms predict poor 6 week outcome in SSRI treatment and correlate with day 7 nocturnal activity by D. Christmas; S.J.C. Davies; D.A. Hince; J. Williams; K. Schroeder; D.J. Nutt (S544-S545).
P.4.c.005 Anxiety treatment and health related quality of life improvement with sertraline of outpatients with chronic heart failure by N. Ibishi; V. Kola; N. Musliu (S544).
P.4.c.001 Efficacy of repetitive transcranial magnetic stimulations in the management of obsessive compulsive disorder by H. EL-Sawy; A.D.E.L. Badawy; M. Abdelhay (S541-S542).
P.4.b.020 Serum BDNF in OCD and major depressive disorder patients before and during antidepressant treatment by L. Bocchio Chiavetto; G. Rosso; R. Zanardini; A. Chiarle; F. Bogetto; M. Gennarelli; G. Maina (S541).
P.4.c.002 Anxiolytic effect of cannabidiol in subjects with social anxiety disorder by M.M. Bergamaschi; M.H.N. Chagas; D.I. Chaves; B.S. Martinis; M.D. Grando; M.C. Freitas; R.H.C. Queiroz; J.E.C. Hallak; A.W. Zuardi; J.A.S. Crippa (S542).
P.4.c.003 Ondansetron augmentation in resistant OCD: relapse in symptoms following discontinuation of ondansetron by S. Pallanti; S. Antonini; S. Bernardi; E. Hollander (S542-S543).
P.4.c.004 Comparison of effect of paroxetine and milnacipran for outpatients with pain disorder by K. Sanada; M. Mimura; Y. Noda; M. Hida; M. Nakahara; A. Tsukurimichi; Y. Kawamura; N. Kato (S543).
P.4.e.004 SSRI treatment-induced weight loss is associated with a 5-HT2C receptor polymorphism by M.M. Oros; O.O. Yevtushenko; G.P. Reynolds (S548).
P.4.e.005 Obsessionality in the general population and in psychiatric disorders by R.M. Blom; C. de Bruijn; R. de Graaf; M. ten Have; D. Denys (S548-S549).
P.5.a.008 The effectiveness of risperidone on behavioural and psychological symptoms of dementia by C.H. Lee; Y.D. Kim; D.-Hee Kim; D.-Hong Kim (S554).
P.5.a.007 Comparative efficacy of cholinesterase inhibitors in dementia associated with Parkinson's disease by D. Vasile; O. Vasiliu; M.L. Vasile; M. Terpan; G. Grigorescu; V. Bogdan; A. Mangalagiu; M.B. Petrescu; D. Ojog (S553-S554).
P.5.a.009 Relationship between subjective memory complaints and cognitive function in the elderly by K.Y. Lim; K.J. Chang; K.S. Lee; H.J. Kim; H.K. Cheong; B.H. Oh; C.H. Hong (S554-S555).
P.5.a.010 Association between memory age identity and cognition in the elderly by K.Y. Lim; K.J. Chang; H.J. Kim; K.S. Lee; H.K. Cheong; B.H. Oh; C.H. Hong (S555).
P.5.a.011 Correlation of plasma homocysteien and folate levels with white matter changes in Alzheimer's disease patients by S.G. Kim; H.Y. Jung; S.Y. Lee; E.Y. Shin; W.Y. Jung; J.H. Park (S556).
P.5.a.006 Methylphenidate augmentation of cholinesterase inhibitors for the treatment of apathy associated with Alzheimer's disease by I. Paik (S553).
P.5.a.005 An open label study of mirtazapine in the treatment of depression with Alzheimer's disease by W. Hahm (S552).
P.5.a.001 Disease system analysis approach to model Alzheimer's disease progression in patients on stable acetylcholine esterase inhibitor therapy by R. Gomeni; M. Gold; M. Zvartau-Hind; M. Irizarry; D. Austin; M. Simeoni (S550).
P.4.e.006 Aripiprazole augmentation of antidepressant therapy of severe obsessive-compulsive disorder: a preliminary study by M. Casale; R. Braiotta; C. Cerruti; E.P. Di Pierro; T. Guerriero; F. Maucioni; A. Morello; T. Tortorella; A. Mautone (S549).
P.5.a.002 Accessing treatment and services for people with dementia: a pilot study by R. Spencer; S. Curran; N. Roberts; V. Minogue; J. Shewan; J. Wattis (S550-S551).
P.5.a.003 The validity of the Korean version of brief cognitive rating scale (BCRS) by Y. Choi (S551).
P.5.a.004 Effect of food supplement F containing ferulic acid and angelica archangelica on behavioural disorder of dementia by K. Kanaya; S. Abe; M. Sakai; H. Fujii; K. Koizumi; T. Iwamoto (S552).
P.4.b.019 Panic attacks associated with generalised anxiety disorder by M. Van Ameringen; C. Mancini; W. Simpson; B. Patterson (S540).
P.4.b.018 Examining face and construct validity of a non-invasive model of panic disorder in lister-hooded rats by E. Prinssen; L.B. Nicolas; C. Lopez Lopez; L.H. Jacobson; S. Gatti; C. Grundschober; S. Klein (S539-S540).
P.4.a.016 Occurrence of traumatic brain injuries in patients with chronic posttraumatic stress disorder by M. Simonovic; M. Radisavljevic; G. Grbesa (S529-S530).
P.4.a.015 Investigation of predictors of drug response in obsessive compulsive disorder (OCD) by P. Richter; K. Witheridge; Z.J. Daskalakis; J. Deluce; R. Nebitt; N. Rector; A. Levitt; J.L. Kennedy (S529).
P.4.b.002 Effects of novel 3,4-dimethoxyphenyl-ethylamine derivates on anxiety-like behaviour: a pilot study by J. Fedotova; V. Barishpolec; G. Markarov (S530-S531).
P.4.b.003 Distinct role of the ventral hippocampus in two different animal models of anxiety by V.C.S. Amaral; R.L. Nunes-de-Souza (S531).
P.4.b.004 Investigation of effects of fluoxetine on unpredictable chronic mild stress-induced changes of brain tissue by Fourier transform mid-infrared spectroscopy by S. Turker; O. Mutlu; I. Komsuoglu; E. Gumuslu; F. Yildiz; F. Erden (S531-S532).
P.4.a.014 Alcohol use and drinking motivation in posttraumatic stress disorder patients: a case-control study by H. So; H. Jung; J. Choi; T. Kim; M. Chung; S. Lee (S528-S529).
P.4.a.013 Critical elements of cognitive behavioural therapy (CBT) for panic disorder with agoraphobia: a preliminary examination of the influence of exposure by A.T. Gloster; M. Höfler; H.U. Wittchen (S527-S528).
P.4.a.009 Efficacy of pregabalin in generalised social anxiety disorder: results of a placebo-controlled, fixed-dose study by D. Feltner; R. Bielski; M. Liu-Dumaw (S525-S526).
P.4.a.008 Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder by J. Greist; M. Liu-Dumaw; D. Feltner (S525).
P.4.a.010 Evaluation of the pharmacokinetics and clinical tolerability of the novel anxiolytic BNC210 in healthy volunteers by G. Kremmidiotis; S. O'Connor; E. Doolin; P. Rolan (S526).
P.4.a.011 Neuropsychological effects of nucleus accumbens deep brain stimulation surgery for obsessive-compulsive disorder by M. Mantione; D. Nieman; R. Schuurman; D. Denys (S526-S527).
P.4.a.012 Preliminary results of therapists' adherence in a randomised clinical cognitive-behavioural therapy trial for panic disorder and agoraphobia by C. Hauke; A.T. Gloster; H.U. Wittchen (S527).
P.4.b.005 Type-2 cannabinoid receptor (CB2r) overexpression results in reduced response to anxiogenic-like stimuli and impaired anxiolytic action of alprazolam by M. García-Gutiérrez; J. Manzanares (S532).
P.4.b.006 Interpreting the social scene: threat detection and cost attribution in social anxiety by K.S. Button; M.R. Munafò; G. Lewis (S533).
P.4.b.014 Effects of diazepam on fear behaviours evoked by a model of panic involving prey versus predator confrontations by A. Francisco; M.A. Castiblanco-Urbina; A. Twardowschy; A. Uribe-Mariño; N.C. Coimbra (S537-S538).
P.4.b.013 Effect of diazepam on conditioned fear evoked by an ethological model of panic involving prey versus predator encounters by M.A. Castiblanco-Urbina; A. Twardowschy; A. Uribe-Mariño; A. Francisco; N.C. Coimbra (S536-S537).
P.4.b.015 Development of autistic symptoms under chronic social defeat stress in anxious male mice: effects of diazepam by N.N. Kudryavtseva; I.L. Kovalenko (S538).
P.4.b.016 Ventromedial prefrontal cortex activity is required for anxiety expression: distinct neurochemical mechanisms evidence by C.A.J. Stern; F.H. Do-Monte; L. Gazarini; A.P. Carobrez; L.J. Bertoglio (S538-S539).
P.4.b.017 D2 dopamine receptor (DRD2) gene polymorphism and combat-related posttraumatic stress disorder in Vietnam veterans by J.H. Choi; T.Y. Kim; K. Kim (S539).
P.4.b.012 Acute anxiolytic drug treatment has no effect on the instrumental successive negative contrast effect using a modified forced choice serial reaction time task by E.N. Mitchell; H. Marston; D. Nutt; E.S.J. Robinson (S536).
P.4.b.0111 The aversive state induced by periaqueductal gray stimulation modulates the reconsolidation of a fear memory by C. Mochny; G.C. Kincheski; V.A. Molina; A.P. Carobrez (S535-S536).
P.4.b.008 Beta-adrenoceptor stimulation by isoproterenol promotes olfactory fear conditioning in rats by E. Pavesi; N.S. Canteras; A.P. Carobrez (S534).
P.4.b.007 Effects of ventrolateral periaqueductal gray lesion on nociception, locomotion and anxiety-like indices in mice by J. Mendes-Gomes; R.L. Nunes-de-Souza (S533).
P.4.b.009 Posttraumatic stress disorder and inflammation by G. Mkrtchyan; L. Hovhannisyan; A. Boyajyan; M. Tadevosyan; A. Kalashyan; S. Sukiasian (S534-S535).
P.4.b.00l Neuropeptide S receptor (NPSR) gene – imaging genetic evidence for a role in panic disorder by K. Domschke; P. Ohrmann; A. Pedersen; C. Hohoff; J. Bauer; T. Suslow; H. Kugel; V. Arolt; A. Reif; J. Deckert (S530).
P.4.b.010 Coping strategies in depression and/or panic disorder compared to healthy controls by L. Timmerman; R. Ploeger (S535).
P.5.a.012 Effects of memantine on global clinical status in patients with moderate Alzheimer's disease by S.M. Graham; R.K. Hofbauer; S. Hendrix; M. Tocco; J.L. Perhach (S556-S557).
P.5.a.013 Memantine prevents worsening across multiple domains in a trial of patients with moderate Alzheimer's disease by S.M. Graham; M. Tocco; S. Hendrix; R.K. Hofbauer; M.L. Miller; J.L. Perhach (S557).
P.6.b.002 Can behaviour during computer assisted self-infusion of ethanol (CASE) predict the future risk for addiction? by I. Mick; S. O'Connor; V. Vitvitskiy; P. Winiecki; K.F. Mann; U.S. Zimmermann (S577).
P.6.b.001 Ethanol inhibits neurotransmission in the nucleus accumbens of juvenile mice through the activation of GABA receptors by D. Mishra; K. Chergui (S576-S577).
P.6.b.003 Effects of acute alcohol consumption on response inhibition of salience attribution by S. Adams; A.F. Ataya; M.R. Munafò (S577-S578).
P.6.b.004 Milnacipran reduces alcohol-induced behaviours, alcohol self-administration and relapse in dependent rats by M. Naassila; E. Simon O'Brien; R. Legastelois; H. Houchi; C. Vilpoux; S. Alaux; O. Pierrefiche; E. André (S578-S579).
P.6.b.005 Alterations of nerve growth factor expression and promoter methylation during alcohol withdrawal by T. Hillemacher; M.A. Muschler; H. Frieling; S. Bleich; A. Heberlein (S579).
P.6.a.011 Adequacy of decision making is not associated with long-term abstinence in alcohol addiction by B. Andó; A. Szkaliczki; E. Kurgyis; N. Domján; J. Honti; I. Demeter; P. Szikszay; Z. Janka; P. Almos (S576).
P.6.a.010 Alterations of brain-derived neurotrophic factor serum levels in alcohol dependence patients by R. Zanardini; A. Fontana; M. Gennarelli; L. Bocchio-Chiavetto (S575-S576).
P.6.a.006 Clinical variables related to attentional bias associated with alcohol cues by F. Trujillo; M. Marín; J. Chamorro; P. Curibil; L. Sánchez-Pastor; I. Martínez-Gras; G. Ponce; G. Rubio (S573).
P.6.a.005 Inpatient alcoholics and level of motivation for abstinence using university of Rhode Island change assessment scale by B.J. Jung; D.K. Lee; H.J. Kim (S572-S573).
P.6.a.007 Influence of neuroactive peptidic preparations on apoptosis of immunocompetent cells in alcoholic patients by N. Bokhan; E.V. Zhernova; S.A. Ivanova (S574).
P.6.a.008 Changes in alcohol use following flood disaster according to pre-disaster alcohol use: a 2-year prospective study by J. Shin; M.H. Kim; S. Min (S574-S575).
P.6.a.009 Profiling Type I and Type II alcoholics using psychometric questionnaires in a Greek patient sample by G. Ntantouti; G. Kiosterakis; E. Segredou (S575).
P.6.b.006 The psychosocial factors affecting drinking behaviours in Korean young adults with variant ALDH2 genotype by S. Kim; S. Lee; J. Son; C. Shin (S579-S580).
P.6.b.007 Alcohol induce selective alterations on opioid system genes regulation in rat amygdala: possible epigenetic mechanisms by C. D'Addario; F.F. Caputi; S. Candeletti; R. Rimondini; P. Romualdi (S580).
P.6.c.007 A comparison of methadone-maintained patients with and without co-occuring personality disorder by K. Stoychev; K.M. Ivanov; M.G. Alexandrova; R.D. Stoychev (S585).
P.6.c.006 Six month follow-up of cocaine users admitted in an outpatient treatment centre in Barcelona (Spain) by C. Castillo; D. Martinez; R. Martinez; P. Rossi; F. Fonseca; M. Astals; G. Mairal; L.L. Tort; M. Torrens (S584-S585).
P.6.c.008 Respiratory changes following benzodiazepine administration in opioid-dependent human participants by T.M. Williams; R. Lees; R.M. Lovell; G. Henderson; D.J. Nutt; A. Lingford-Hughes (S585-S586).
P.6.c.009 Eplivanserin has no significant abuse potential compared to diazepam and ketamine in recreational drug users by K.A. Schoedel; S. Saubadu; A. Delfolie; J.L. Pinquier; E.M. Sellers (S586-S587).
P.6.c.010 Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users by K.A. Schoedel; N. Chen; G.W. Guy; S. Wright; A. Patel; L. White; C.G. Stott; E. Russo; E.M. Sellers (S587).
P.6.c.005 Attentional bias towards cocaine cues using a dot-probe detection task by G. Rubio; J. Chamorro; S. Moratti; I. Martínez-Gras; P. Campo; G. Ponce (S584).
P.6.c.004 Neurocognitive endophenotypes of stimulant dependence – preliminary findings by S. Pradhan; A.J. Turton; T.W. Robbins; E.T. Bullmore; K.D. Ersche (S583-S584).
P.6.b.009 Alcohol intoxications during adolescence predict later vulnerability to alcohol self-administration in rats by M. Naassila; V. Warnault; M. Kervern; O. Pierrefiche; C. Vilpoux; S. Alaux (S581).
P.6.b.008 Cognitive bias in social alcohol consumers: do stimuli matter? by A. Ataya; S. Adams; M.R. Munafò (S580-S581).
P.6.c.001 Cortisol levels and MDMA-induced memory impairment by K.P.C. Kuypers; J.G. Ramaekers (S581-S582).
P.6.c.002 Impulsivity – an inherited vulnerability marker for stimulant dependence? Preliminary findings by A.J. Turton; S. Pradhan; E.T. Bullmore; T.W. Robbins; K.D. Ersche (S582-S583).
P.6.c.003 Association of the CHRNA5-A3-B4 gene cluster with heaviness of smoking by J. Ware; M. Munafò; M. Van Den Bree (S583).
P.6.a.004 Serum glutamate dehydrogenase in alcoholics by M. Kravos; I. Maleic (S572).
P.6.a.003 Long acting risperidone in heavy-drinkers: a preliminary study of efficacy by M. Marinescu; S. Bisleau; V. Ferri; S. Bulteau; S. Voillet; S. Pradayrol; Y. Bescond; M. Lejoyeux (S571-S572).
P.5.c.001 Memantine improves poststroke cognitive impairment supported with mirtazapine by S. Djukic Dejanovic; D. Djokic; D.R. Milovanovic; M. Borovcanin; D.B. Ravanic (S562).
P.5.b.003 Psychopharmacological intervention in cognitive impairment comorbid with medical and/or psychiatric pathology by A.I. Ledo; I. Sanchez; I. López; A. Soto; P. Marqués (S561-S562).
P.5.c.002 Eating disorders and deep brain stimulation of the subthalamic nucleus in Parkinson's Disease by I. Chéreau; I. De Chazeron; I. Rieu; P.p. Derost; J.j. Lemaire; P.m. Llorca; F. Durif (S562-S563).
P.5.c.003 Psychiatric comorbidity and quality of life in patients candidates to epilepsy surgery by L. Camara Pestana; M. Andreia; A. Carmo; R. Mendes; S. Loureiro (S563).
P.5.d.001 1-Benzyl-1,2,3,4-tetrahydroisoquinoline inhibits L-DOPA-induced increase of dopamine metabolism in rat brain by A. Wasik; M. Kajta; I. Romanska; L. Antkiewicz-Michaluk (S563-S564).
P.5.b.002 Neuroprotective therapy in basic treatment of vascular dementia by I. Suvorova; V. Shprakh (S561).
P.5.b.001 Longitudinal [11C]PIB and [18F]FDDNP PET studies on memory in patients and controls by R. Ossenkoppele; N. Tolboom; W.M. van der Flier; M. Yaqub; A.D. Windhorst; R. Boellaard; F. Barkhof; A.A. Lammertsma; P. Scheltens; B.N.M. van Berckel (S560-S561).
P.5.a.015 Psychometric properties of the Turkish version of the Cohen-Mansfield agitation inventory by E.T. Ozel-Kizil; G. Bastug; S. Erdogan; D. Sakarya (S558).
P.5.a.014 Functional communication in patients with moderate Alzheimer's disease treated with memantine by S. Graham; M. Tocco; S. Hendrix; R.K. Hofbauer; J.L. Perhach (S557-S558).
P.5.a.016 Automated classification of MR images for recognising Alzheimer's disease in living patients by F. Simsek; F. Polat; O. Demirel; O. Kitis; D. Haznedaroglu; C. Eker; E. Kumral; A.S. Gonul (S558-S559).
P.5.a.017 Effects of memantine on language and functional communication in patients with moderate to severe Alzheimer's disease by M. Tocco; S.M. Graham (S559).
P.5.a.018 Validity of semantic memory test as predictor of change in ADAS-cog scores in mild cognitive impairment by E. Kornsey; B. Friedmann; M. Murphy; N. Cutler (S560).
P.5.d.002 The protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on rotenone-induced irregularities in rat brain by L. Antkiewicz-Michaluk; A. Wasik; I. Romanska; J. Boksa; J. Michaluk (S564-S565).
P.5.d.003 Effects of resveratrol on scopolamine and mecamylamine induced memory impairment in rats by N. Gacar; T. Utkan; O. Mutlu; S.S. Göçmez; I. Komsuoglu Celikyurt; G. Ulak (S565).
P.5.e.004 The impact of site rater monitoring and refresher training on enrollment in a mild cognitive impairment phenotype trial by B. Friedmann; E. Kornsey; M. Murphy; N. Cutler (S569-S570).
P.5.e.003 ZOOM: observational genetic screening study of Niemann-Pick disease type C in adults with neurological/psychiatric signs by H. Klünemann; F. Sedel; D. Linden; D. Balding; J.E. Wraith; M.C. Patterson; M. Pineda; J. Priller; C. Remy; P. Bauer (S569).
P.5.f.001 Age-related changes in brain white matter hyperintensities of Korean elderly: its impact on mood and cognition by H.S. Kim; B.I. Yoo; T.H. Kim; K.W. Kim (S570).
P.6.a.001 Differences in the clinical features and temperament and character between hospitalised male and female alcoholics by J.S. Lee; S.B. Lee (S570-S571).
P.6.a.002 Clinical trial of escitalopram for alcoholism comorbid with affective disorders by E. Krupitsky; S. Yerish; A. Kiselev (S571).
P.5.e.002 Comparison between effectiveness of aripiprazole and risperidone for treatment of delirium in hospitalized patients by J.K. Sakong; S.W. Jung; J.S. Kim; B.H. Koo (S568-S569).
P.5.e.001 Patient characteristics for misdiagnosed delirium at psychiatric consultation in a university hospital by K.W. Yun; J.W. Choi; H.S. Park; J.H. Ryoo; Y.C. Kim; W.J. Lim; E.J. Kim; S.I. Kim (S567-S568).
P.5.d.004 Neuroprotective effect of cerebrolysin and erythropoietin versus haloperidol in an Alzheimer's disease – animal model by L. Mogoanta; D. Marinescu; T. Udristoiu; I. Udristoiu; D. Pirici (S565-S566).
P.5.d.005 Midazolam microinjected into inferior colliculus potentiate haloperidol-induced catalepsy by L. Melo; J.G. Tostes; P. Medeiros; N.C. Coimbra; E.A.M. Ferrari (S566).
P.5.d.006 Pro-and antioxidant mechanisms in patients in different clinical forms of multiple sclerosis current in treatment by L. Smirnova; N. Krotenko; V. Alifirova (S566-S567).
P.5.d.007 Effects of 5-HT7 receptor ligands in rats suffering from chronic neuropathic pain by F. Viguier; B. Michot; V. Kayser; M. Hamon; S. Bourgoin (S567).
P.2.d.008 Effects of single and chronic agomelatine administration on Galpha(i) proteins expression in the rat brain by P. Chmielarz; K. Wieczerzak; A. Zelek-Molik; J. Kusmierczyk; A. Bielawski; I. Nalepa (S394-S395).
P.2.d.007 The influence of aripiprazole on the antidepressant and memory improving effects in rats by E. Nowakowska; L. Kus; A. Czubak; K. Burda; J. Zin; P. Ratajczak (S394).
P.1.a.015 Association of schizophrenia and dopamine β-hydroxylase (DBH) polymorphism in Korean population by D.S. Moon; J.W. Paik; A.R. Cho; J.W. Kim; E.J. Kim; J.H. Chung (S220-S221).
P.1.a.014 Association between polymorphisms of arachidonate 12-lipoxygenase (ALOX12) and schizophrenia in Korean population by D.S. Moon; J.W. Paik; A.R. Cho; J.W. Kim; J.H. Chung; E.J. Kim (S220).
P.1.a.016 Biochemical and genomical characteristic of mice lacking the noradrenalin transporter by J. Solich; P. Palach; M. Kusmider; M. Gaska; A. Faron-Gorecka; M. Dziedzicka-Wasylewska (S221-S222).
P.1.a.017 Effect of a functional NOS1 promoter polymorphism and life events on personality, anxiety and depressiveness by J. Harro; T. Kurrikoff; A. Reif; E. Kiive; S. Herterich; T. Tulviste; T. Veidebaum; K.P. Lesch (S222).
P.1.a.018 Alzheimer's disease risk and polymorphisms of the DHCR24 gene by A. Feher; A. Juhasz; A. Rimanoczy; J. Kalman; Z. Janka (S222-S223).
P.1.a.013 In silico analysis of expression of orphan G protein-coupled receptor 155 during inflammation – implications for autism by A.H. Swiergiel; G.R. Juszczak; K.M. Grochowska (S219-S220).
P.1.a.012 Association of aggressive traits with the 5-HTTLPR polymorphism in depressed and healthy women by X. Gonda; K.N. Fountoulakis; J. Lazary; D. Pap; M. Sasvari-Szekely; A. Veres-Szekely; G. Bagdy; G. Faludi; Z. Rihmer (S219).
P.1.a.007 Neurotrophin family genes (BDNF and NTRK2) and personality traits in healthy individuals by A. Kazantseva; A. Khannanova; T. Traks; S. Koks; E. Khusnutdinova (S216-S217).
P.1.a.006 Association between circadian gene polymorphisms and posttraumatic stress symptoms in Korean young females by K. Choi; E. Joo (S216).
P.1.a.009 Association study of DISC1 gene with cognitive functions in Korean schizophrenia patients and healthy controls by D. Park; H. Park; T. Park; S. Oh; E. Cho; N. Kim; K. Hong (S217).
P.1.a.010 The role of sigma-1 receptor polymorphism in the pathogenesis of Alzheimer's disease: preliminary results by A. Juhasz; A. Feher; A. Rimanoczy; M. Galfi; J. Kalman; Z. Janka (S218).
P.1.a.011 The study of prolactin gene polymophism in schizophrenic patients by J.K. Rybakowski; M. Dmitrzak-Weglarz; P. Kapelski; J. Hauser (S218-S219).
P.1.a.019 Case-report of Charcot-Marie-Tooth disease in a patient with alcohol dependence by S. Ilut; M. Valcu; V. Vacaras; L. Fodoreanu (S223).
P.1.a.020 Expression of calcyon gene in rat brain after stressfull behavioural procedures by M. Kusmider; A. Faron-Gorecka; M. Gaska; P. Gruca; M. Papp; M. Dziedzicka-Wasylewska (S223-S224).
P.1.b.004 White matter microstructural alterations of the extrastriate visual cortex in women with anorexia nervosa by H. Frieling; T. Peschel; J. Fischer; T. Engelhorn; T. Hillemacher; S. Bleich; M. de Zwaan (S229).
P.1.b.003 The correlation between self-rated stress response and short-term heart rate variability (HRV) in healthy females by J. Woo; T. Kim; J. Dimsdale (S228-S229).
P.1.b.005 Three dimensional electroencephalographic mapping with eLORETA during sleep onset period by D. Park; C. Shin (S230).
P.1.b.006 Detrended fluctuation analysis during sleep onset period by C. Shin; D. Park (S230).
P.1.b.007 Emotional face processing in the 5-HT2A model of altered states of consciousness using event-related potentials by A. Schmidt; P.A. Csomor; R. Bachmann; M. Kometer; F.X. Vollenweider (S231).
P.1.b.002 Motor tract white matter correlates with volitional motor behaviour in schizophrenia by S. Walther; H. Horn; A. Federspiel; N. Razavi; T. Dierks; W. Strik; T.J. Müller (S228).
P.1.b.001 Repetitive transcranial magnetic stimulation (rTMS) in the treatment of neuropatic pain by M. Klirova; J. Fricova; P. Sos; T. Novak; B. Tislerova; M. Haeckel; V. Masopust; R. Rokyta (S227-S228).
P.1.a.022 Preliminary study investigating the interferon gamma +874 T/A polymorphism and the somatic type of depression by T. Rimay; G. Daroczi; E. Kovacs; I. Benak; A. Feher; A. Juhasz; A. Vetro; M. Kovacs (S225).
P.1.a.021 Effects of desipramine treatment on hippocampal transcriptome in mice differing in responses to antidepressants by P. Lisowski; G.R. Juszczak; J. Goscik; L. Zwierzchowski; M. Wieczorek; A.H. Swiergiel (S224-S225).
P.1.a.023 Reduced sensitivity to nociceptive stimuli in mutant mice with low glutamatergic tone in the central nervous system by V. Kayser; M. Melfort; J. Masson; M. Hamon; S. Bourgoin (S225-S226).
P.1.a.024 Brain-derived neurotrophic factor gene polymorphism Val66Met, personality traits and academic success by K. Hiio; J. Parik; H.M. Loit; J. Harro (S226).
P.1.a.025 Antipsychotics-induced weight gain and the 5-HT2A and 5-HT6 receptor gene polymorphisms in Korean schizophrenic patients by H.C. Kim; Y.A. Kim; S.W. Jung; D.K. Kim (S227).
P.1.a.005 A pilot study for family based association analysis of qualitative and quantitative traits for Korean schizophrenics by B. Lee; D. Kwon; Y. Kim; Y. Chung; J. Park; S. Kim; C. Kang; J. Kim; Y. Lee (S215-S216).
P.1.a.004 Associations between AVPR1b and NR3C1 gene variants and HPA axis responses to psychosocial stress by D. van West; J. Del-Favero; D. Deboutte; C. Van Broeckhoven; S. Claes (S214-S215).
S.27.04 Harmful psychiatric effects of plant cannabinoids in humans by C. Henquet; R. Kuepper; M. Konings; J. Van Os (S206).
S.27.03 The endocannabinoid system in neurodegeneration and psychiatry by K. Van Laere (S205-S206).
S.27.05 Targeted cognitive-behavioral treatment for cannabis use disorders (CANDIS): efficacy, longterm stability, and efficiency by H. Wittchen (S206).
S.28.01 Pathology of astroglia, GABA interneurons and pyramidal glutamatergic neurons in postmortem prefrontal cortex in major depression: relevance to neuroimaging studies by J.J. Miguel-Hidalgo; G. Rajkowska (S207).
S.28.02 Glutamate and the prefrontal cortex in the psychopathology of depression – a combined fMRI-MRS approach by G. Northoff (S207).
S.27.02 Plant cannabinoids and psychiatric disorders: preclinical findings by D. Parolaro; D. Vigano; E. Zamberletti; C. Guidali; N. Realini; T. Rubino (S205).
S.27.01 Pharmacological actions of cannabinoids by R. Pertwee (S205).
S.26.02 Brain mechanisms in PTSD by E. Vermetten (S203).
S.26.01 An innovative animal model of PTSD and its role in translational research by M.A. Matar; J. Zohar; H. Cohen (S203).
S.26.03 PTSD and physical illness by C. Spitzer; B. Löwe; S. Barnow; H.J. Grabe (S204).
S.26.04 Molecular neuroscience of PTSD by D.J. Stein (S204).
S.26.05 Early pharmacological intervention in PTSD: an update by J. Zohar (S204-S205).
S.28.03 Abnormalities of glutamate and GABA systems in depression: novel findings from studies using MRS and PET by G. Hasler; A. Deschwanden; B. Karolewicz; F. Buck; S.M. Ametamey; W.C. Drevets; J.W. Van der Veen; J. Shen; V. Treyer (S207-S208).
S.28.04 The antidepressant potential of mGluR5 and GABA-B receptor antagonists in rodent models of depression by A. Pilc; A. Palucha-Poniewiera; J. Wieronska; K. Stachowicz; P. Branski; A. Siwek; M. Dybala; G. Nowak (S208).
E.06.01 The stroke patient as a challenge for the psychiatrist by S. Starkstein (S212).
E.05.02 Metabolic alterations and their background in patients with affective disorders by K. Kahl; S. Lampen-Inkamp; B. Claassen; T. Peschel; G. Schik (S211).
P.1.a.001 Migraine and cardiovascular diseases:role of ACE and MTHFR genes polymorphisms by A. Capasso; A. Bisogno; A. Agresta; V. Pizza (S213).
P.1.a.002 DTNBP1, HSPs and TAAR6 variations influence schizophrenic phenotype and treatment response by C. Pae; A. Drago; A. Serretti (S213-S214).
P.1.a.003 Pharmacogenetic study on metabolic syndrome induced by atypical antipsychotics and mood stabilizers by G. Bondolfi; E. Choong; M. Etter; B. Oneda; H. Tayebi; J.M. Aubry; C.B. Eap (S214).
E.04.03 When should deep brain stimulation (DBS) be considered as a potential treatment for patients with treatment resistant depression? by T. Schläpfer; B. Bewernick; S. Kayser; B. Hadrysiewicz (S211).
E.04.02 Clinical predictors and drugs interactions of transcranial magnetic stimulation (TMS) by K.P. Ebmeier; C.L. Allan; L.L. Herrmann (S210).
E.01.01 Compulsivity in preclinical research by T. Robbins (S209).
S.28.05 Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole by G. Sanacora; M. Banasr; G. Chowdhury; A. Lepak; K. Behar (S208).
E.01.02 Compulsivity across psychiatric disorders by D. Denys (S209).
E.02.01 Psychotropic drugs and pain mechanisms by J.A. Mico; E. Berrocoso (S209-S210).
E.04.01 Electroconvulsive therapy (ECT) by H. Sackeim (S210).
P.1.b.008 Post imperative negative variation as an endophenotypic marker of schizophrenia? by P. Castro; P. d'Alcantara; G. Cheron (S231-S232).
P.1.b.009 Effect of cobalt chloride into periaqueductal gray matter on panic reactions organized by the medial hypotalamus by M.A. Castiblanco-Urbina; A. Uribe-Mariño; N.C. Coimbra (S232).
P.1.c.032 Interaction study between almorexant, a dual orexin receptor antagonist, and desipramine in healthy male subjects by H. Cruz; P. Hoever; J. Hay; F. Alessi; J. Dingemanse; J. van Gerven (S253).
P.1.c.031 Effect of almorexant treatment on sleep variables in patients with primary insomnia compared with healthy controls by G. Dorffner; P. Anderer; B. Saletu; G.M. Saletu-Zyhlarz; H. Danker-Hopfe; J. Black; J. Dingemanse; P. Hoever (S252-S253).
P.1.c.033 Effect of once-daily almorexant treatment for 6 weeks on the sleep-wake cycle of normal Wistar rats by C. Brisbare-Roch; C. Fischer; F. Jenck (S253-S254).
P.1.c.034 Dorsal raphe nucleus a1, a2 and beta; noradrenergic receptors modulate panic reactions organised by the medial hypothalamus by A. Uribe-Mariño; M.A. Castiblanco-Urbina; N.C. Coimbra (S254).
P.1.c.035 Role of 5-HT1A receptor on innate fear behavioural attentuation by cannabidiol in a prey versus predator paradigm by A. Uribe-Mariño; A. Francisco; M.A. Castiblanco-Urbina; A. Twardowschy; C.J. Salgado-Rohner; J.A.S. Crippa; J.E.C. Hallak; N.C. Coimbra (S255).
P.1.c.030 Second messengers in obsessive-compulsive disorder: role of adenylate-cyclase by D. Marazziti; S. Baroni; G. Consoli; M. Catena Dell'Osso; G. Giannaccini (S251-S252).
P.1.c.029 Effects of pregabalin and topiramate on impulsivity and certain impulsive-related behaviors by F. Navarrete; J.M. Pérez-Ortiz; J. Manzanares (S251).
P.1.c.025 Longterm safety and efficacy outcomes in adults with ADHD treated with prolonged-release methylphenidate by B. Schaeuble; M. Hofecker; J. Buitelaar; S. Kooij; J. Dejonckheere; S. Waechter (S249).
P.1.c.024 A study of the effect of lamotrigine on two convulsive tests in mice by D. Getova; A. Mihaylova (S248).
P.1.c.026 Delayed effects of nociceptin analogue administration to anxiety and learning in juvenile rats by E.A. Ivanova; A.V. Malyshev; N.Y. Sarycheva; V.A. Dubynin; V.N. Kalikhevich; Z.A. Ardemasova; A.A. Kamensky (S249-S250).
P.1.c.027 Glucocorticoid receptors selectively modulate stress-evoked dopamine release in the prefrontal cortex by K. Butts; G. Vacca; S. Ahn; J. Weinberg; A.G. Phillips; A.H. Young (S250).
P.1.c.028 The effects of atypical antipsychotic drugs on regulation of cell cycle against MPP+-induced apoptosis in PC12 cells by Y.H. Kim; H.Y. Cho; S.W. Park; J.G. Lee (S250-S251).
P.1.c.036 Nitric oxide modulation of memantine-induced deficits in sensorimotor gating in rats by C. Salum; N.F. Henriques-Santos; M.C. Brosco; E.A. DelBel (S255-S256).
P.1.c.037 The profile of attentional deficits in schizophrenia: implications for pharmacotherapy by K.A. Wesnes; H. Brooker; C.J. Edgar; H. Hassman (S256).
P.1.c.046 The involvement of opioidergic receptors in the local peripheral anti-hyperalgesic effect of levetiracetam by A. Micov; M. Tomic; R. Stepanovic-Petrovic (S261).
P.1.c.045 Ex-vivo serotonin 5-HT1A and 5-HT2A receptor occupancy by asenapine: comparison to olanzapine and risperidone by Y.K. Choi; B. Henry; M. Shahid; F. Tarazi (S260-S261).
P.1.c.047 Contribution of a1 subunit-containing GABA-A receptors to diazepam-induced motor impairment by J.M. Divljakovic; M. Van Linn; M.M. Milinkovic; W. Yin; B. Batinic; J.M. Cook; M.M. Savic (S261-S262).
P.1.c.048 Modulating effect of new L-valine derivatives on brain serotonin uptake in aggressive socially isolated mice by E. Encheva; S. Stancheva; L. Alova; L. Tancheva; V.V. Petkov; D. Tsekova (S262-S263).
P.1.c.049 Analysis of interaction between oxcarbazepine and COX-inhibitors in a rat model of inflammatory hyperalgesia by M. Tomic; S. Vuckovic; R. Stepanovic-Petrovic; A. Micov; N. Ugresic; M. Prostran; B. Boskovic (S263).
P.1.c.044 SH-I-048A, a novel positive modulator of GABA-A receptor: in vitro and behavioral profile by S.M. Joksimovic; S. Huang; J. Ramerstorfer; M.M. Milinkovic; J.M. Divljakovic; B.L. Roth; W. Sieghart; M.M. Savic; J.M. Cook (S260).
P.1.c.043 Midazolam impairs acquisition but not consolidation in water maze paradigm by M.M. Milinkovic; J. Samardzic; J.M. Divljakovic; S.M. Joksimovic; T. Timic; M.M. Savic (S259-S260).
P.1.c.039 Risperidone-induced hyperprolactinemia: reversal by aripiprazole by E. Esteban; G. Gomez; L. Pereyra; A. Mont (S257).
P.1.c.038 Psychopharmacological treatment of borderline personality disorder by R. Manzanero; I. Duran; M. Garcia; A. Chinchilla; A. Cebollada; M. Vega; A. Soto (S256-S257).
P.1.c.040 Impulsive aggression in a patient treated with levetiracetam by J.L. Villegas Martinez; J.A. Blanco Garrote; P. Marques Cabezas; G. Cabus Piñol; J. Coullaut García (S257-S258).
P.1.c.041 Interaction study between almorexant, a dual orexin receptor antagonist, and ethanol in healthy subjects by M. Hoch; J. Hay; P. Hoever; M. de Kam; J. van Gerven; J. Dingemanse (S258-S259).
P.1.c.042 The effects of variation in magnesium soft matter vesicles dosage on behavioural manifestation in rats by L. Tartau; V. Sindrilar; V. Melnig (S259).
P.1.c.023 Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach by K. Vucicevic; B. Miljkovic; M. Pokrajac; M. Prostran; Z. Martinovic; R. Velickovic; I. Grabnar (S247-S248).
P.1.c.022 Involvement of opioid and GABA receptors in the antinociceptive effect of tianeptine in mice by R. Suciu; A.C. Suciu; D. Patrascu (S247).
P.1.c.004 Defensive effects of polyprenol-containing drug ropren in a model of subacute hepatosis with encephalopathy in rats by P.D. Shabanov; V.S. Sultanov; V.I. Roshchin; T.V. Nikitina; A.A. Lebedev; E.R. Bychkov; S.N. Proshin (S237).
P.1.c.003 Cannabinoid mediated analgesia in rats with a central noradrenergic lesion modeling depressive-like symptoms by E. Korossy-Mruk; R. Brus; R. Szkilnik; P. Nowak (S236-S237).
P.1.c.005 Angiotensin AT1 receptor blockade prevents memory impairment caused by chronic stress by J. Braszko (S237-S238).
P.1.c.006 Delayed effects of NR2B subunit-specific antagonist Ro 25–6981 on spatial memory in adult rats by O.A. Solovieva; A.T. Proshin; Z.I. Storozheva; V.V. Sherstnev (S238).
P.1.c.007 Effects of selective glutamate mGlu5 receptor antagonist, MPEP, on sleep and wakefulness in the rat by G.L. Scesa; M. Cavas; J.F. Navarro (S239).
P.1.c.002 Biological peculiarities of the analgesic drug – nefopam in rats by P. Nowak; M. Beska; R. Szkilnik (S236).
P.1.c.001 Acute psychomotor, memory and subjective effects of MDMA and THC (co-) administration over time in healthy volunteers by G. Dumont; J. van Hasselt; M. de Kam; J. van Gerven; D. Touw; J. Buitelaar; R. Verkes (S235-S236).
P.1.b.011 Thyroid hormones and exposure to violence in childhood in suicide attempters by C. Sinai; A.L. Nordstrom; P. Nordstrom; J. Jokinen (S233).
P.1.b.010 Skin conductance and electromyographic responses to different auditory stimuli in patients with schizophrenia by V. Bilgic; A. Turkcan; G. Ozgen; S. Akdemir; S. Kara (S232-S233).
P.1.b.012 High prevalence of human herpesvirus 8 in a tunisian sample of schizophrenic patients by Y. El Kissi; N. Hannachi; S. Samoud; S. Gaabout; M. Ayachi; J. Boukadida; B. Ben Hadj Ali (S233-S234).
P.1.b.013 Characteristics of the power spectrum alpha activity in relation to clinical expression of schizophrenia by N. Manuseva; B. Stefanovski (S234-S235).
P.1.b.014 Deep brain stimulation of the nucleus accumbens for therapy-refractory obsessive-compulsive disorder by D. Denys; M. Mantione; M. Figee; P. van den Munckhof; F. Koerselman; H. Westenberg; R. Schuurman (S235).
P.1.c.008 Schizophrenia and neuroactive steroids in males by M. Bicikova; M. Hill; D. Ripova; P. Mohr; R. Hampl (S239-S240).
P.1.c.009 Role of the norepinephrine uptake transporter in the mechanism of action of MDMA (Ecstasy) by C.M. Hysek; M. Ineichen; V.G. Nicola; L. Simmler; M.E. Liechti (S240).
P.1.c.018 Increased serotonin 2c receptor editing in a mouse model of obesity by H. Schellekens; T.G. Dinan; J.F. Cryan (S245).
P.1.c.017 New pathway involved in the alteration of reflex bradycardia in response to stress: study in rats and mice by C. Sevoz-Couche; F. Netzer; J.F. Bernard; M. Hamon; J.J. Benoliel (S244-S245).
P.1.c.019 Effects of diazepam on contextual serial memory and hippocampal corticosterone in stressed middle-aged mice by C. Tronche; D. Beracochea; P. Liscia; M. Coutan; C. Pierard (S245-S246).
P.1.c.020 Effect of mycophenolate mofetil on behavioural and neuroimaging outcomes in transient focal cerebral ischemia in rats by A. Chauhan; K.H. Reeta; Y.K. Gupta; S.K. Mewar; U. Sharma; N.R. Jagannathan (S246).
P.1.c.021 Protective effect of Anacyclus pyrethrum against seizures and seizure-induced cognitive impairment in rats by M. Pahuja; J. Mehla; K.H. Reeta; S. Joshi; Y.K. Gupta (S246-S247).
P.1.c.016 Opposing roles of CB1 and TRPV1 in panic-like responses mediated by dorsal periaqueductal gray by A. Terzian; P. Casarotto; D.C. Aguiar; H. Zangrossi; F.S. Guimarães; C.T. Wotjak; F.A. Moreira (S244).
P.1.c.015 Effects of AMN082, an allosteric positive modulator of presynaptic mGluR7 activity, on sleep-wake states in rats by G. Scesa; M. Cavas; J.F. Navarro (S243-S244).
P.1.c.011 Influence of the structural analogue of AVP(6–9) on training of rats followed with positive and negative reinforcement by A. Belyakova; O.G. Voskresenskaya (S241).
P.1.c.010 Lithium reduces neuropathic pain: involvement of opioid system by H.r. Banafshe; G. Hamidi; A. Mesdaghinia; M. Noorani Arani; M. Honarkar Ramezani (S240-S241).
P.1.c.012 Design, structural characterisation and biocompatibility evaluation of tramadol loaded nanoparticulate systems by L. Tartau; A. Garlea; V. Melnig (S241-S242).
P.1.c.013 A7 nicotinic receptor agonist enhances neurogenesis and reduces brain inflammation after lipopolysaccharide (LPS) or radiation treatment by W. Zhao; S.M. Toler; P.M. Lippiello; M. Bencherif (S242).
P.1.c.014 MBDB, a recreational drug similar to MDMA, exhibits anxiogenic-like effects in mice tested in the elevated plus-maze by A.t. Muela; M. Martin-Lopez; M. Cavas; J.f. Navarro (S243).
S.25.05 Erythropoietin and neuroprotection by H. Ehrenreich (S202-S203).
S.25.04 Cannabinoids and neuroprotection by J. Ferníndez-Ruiz (S202).
S.07.08 Differential response to treatment across countries in a randomized clinical trial in mania by I. Pacchiarotti; E. Pappadopulos; F.S. Mandel; I. Lombardo; A. Loebel; E. Vieta (S174).
S.07.07 Addiction proneness: contribution of the endocannabinoid system and reward processing by H.H. van Hell; G. Jager; A. Brouwer; M.G. Bossong; R.S. Kahn; N.F. Ramsey (S174).
S.08.01 Involvement of hippocampal neurogenesis in the control of the HPA axis: evidence from animal models of affective disease by C. Belzung; A. Surget; A. Tanti; A. Laugeray; Q. Rainer; G. Griebel; R. Hen; C. Touma; P. Ruppert (S174-S175).
S.08.02 Chronic stress, depressive disorders and obesity: insights from animal models by A. Bartolomucci; V. Sanghez; C. Cero; V. Carola; C. Gross; A. Vidal-Puig; Z. Zukowska; S. Parmigiani; P. Palanza (S175).
S.08.03 Early life stress in rodents as predictor for structural and functional neuroplasticity later in life by M. Joëls; F. Van Hasselt; H. Krugers (S175-S176).
S.07.06 Netrin G1 polymorphisms in cocaine and alcohol codependence vulnerability: from mice to men by S. Kelai; G. Maussion; N. Munoz; C. Boni; N. Ramoz; M. Simonneau; P. Gorwood (S173).
S.07.05 Abnormalities in reward prediction error signals in depression and schizophrenia by V. Gradin; P. Kumar; G. Waiter; T. Ahearn; I. Reid; C. Stickle; M. Milders; J. Hall; J.D. Steele (S173).
S.07.01 Role of Cdk5 activators in psychiatric diseases, learning and memory by O. Engmann; T. Hortobagyi; D. Bannerman; A.J. Thompson; K.P. Giese (S171).
S.06.05 Presentation of a large European collaborative study of environmental risk factors for psychosis – the EU GEI environmental work-package by C. Morgan (S171).
S.07.02 Cued but not contextual fear conditioning impairment in the NMDA receptor subunit NR1-DbhCre transgenic mice by W. Solecki; K. Szklarczyk; J. Kubik; M. Sikora; J. Parkitna; R. Przewlocki (S171-S172).
S.07.03 Antidepressant treatment modulates neural responses to self-referential words in subjects with high neuroticism by M. Di Simplicio; R. Norbury; C.J. Harmer (S172).
S.07.04 CYP2D6 genotype predicts antidepressant dose in the GENDEP project by R. Keers; M. Ingelman-Sundberg; J. Hauser; W. Maier; M. Rietschel; O. Mors; P. McGuffin; A.E. Farmer; I.W. Craig; K.J. Aitchison (S172-S173).
S.08.04 Restoring normal synaptic function in frontal netwoks as a new approach to treat mood disorders by T.M. Jay (S176).
S.08.05 New findings on the neurobiology of resilience and susceptibility to social stress by A.J. Eisch; D.C. Lagace; M.H. Donovan; N.A. DeCarolis; L.A. Farnbauch; S. Malhotra; O. Berton; E.J. Nestler; V. Krishnan (S176).
S.10.04 Ghrelin, leptin and other neurohormones involved in concerted regulation of brain and visceral functions by J. Epelbaum; M.C. Bourdel; R. Dardennes; B. Estour; B. Galusca; N. Germain; P.H. Gorwood; D. Grouselle; J.P. Olié; A. Pham-Scottez (S180).
S.10.03 Animal models of co-morbid depression and irritable bowel syndrome by J. Cryan; J.A. Bravo; G. Clarke; N.P. Hyland; D. O'Malley; D. O'Mahony; M. Julio-Pieper; D.P. McKernan; M. Tramullas; T.G. Dinan (S179-S180).
S.10.05 Brain imaging in patients with gastrointestinal disorders by E.A. Mayer; J. Labus; K. Tillisch (S180-S181).
S.12.01 Physiological and therapeutic relevance of constitutive activity at 5-HT2C receptors by U. Spampinato; A. Cathala; G.M. Leggio; M. Neny; F. Rouge-Pont; F. Drago; P.V. Piazza (S181).
S.12.03 Antidepressant-induced functional adaptive changes in 5-HT2C receptors: are they underlying their anxiolytic effects? by R. Mongeau; C.B.P. Martin; C. Chevarin; R. Maldonado; M. Hamon; P. Robledo; L. Lanfumey (S181).
S.10.02 Neurobiological links between visceral dysfunction and affective disorders by P. Holzer; E. Painsipp (S179).
S.10.01 Biological pathways underpinning chronic fatigue, somatisation and psychosomatic symptoms by M. Maes (S179).
S.09.02 Environment and vulnerable physiology in autism by M.R. Herbert (S177).
S.09.01 Whole-brain structural MRI of autism-associated neuroanatomical features by D. Murphy (S177).
S.09.03 Neurotrophic factors in autism by R. Riikonen; I. Makkonen; J. Kuikka; W. Kaufmann; U. Turpeinen; R. Vanhala; H. Kokki (S177-S178).
S.09.04 Mechanisms controlling the development of cortical interneurons: potential implications for Autism Spectrum Disorders by O. Marín (S178).
S.09.05 Neurobiological treatment of autism spectrum disorders: present and future by J. Buitelaar (S178).
S.06.04 NGF and BDNF as neuroendocrine factors involved in the response to early life stress and susceptibility to psychopathology: evidence from animal models by F. Cirulli; L. Aloe; N. Francia; A. Berry; E. Alleva; S.J. Suomi (S170-S171).
S.06.02 Can we explain the epidemiology of schizophrenia in terms of the pathology of striatal dopamine? by R. Murray (S170).
S.02.05 Genetics of tauopathies by J. Hardy (S163).
S.02.04 Physiopathological features of tauopathies and tau transgenic mice by L. Buée; S. Burnouf; L. Troquier; A. Leboucher; C. Laurent; H. Le Freche; J. Brouillette; M. Hamdane; N. Sergeant; D. Blum (S163).
S.03.01 The past, present and future role of the dopamine D2 receptor in schizophrenia by S. Kapur (S163-S164).
S.03.02 Searching for an optimised pharmacological cocktail: focus on antipsychotics with combined D2 and serotonin 5-HT1A activity by A. Newman-Tancredi (S164).
S.03.03 Brain connectivity modulation by novel antipsychotics: an electrophysiological approach by M. Spedding; C. Sebban; T. Jay; E. Schenker; I. Gacsalyi (S164-S165).
S.02.03 Tau toxicity in cell and animal models by E.M. Mandelkow; E. Thies; A. Sydow; Y. Wang; J. Biernat; E. Mandelkow (S162-S163).
S.02.02 Tauopathy causing frontotemporal lobe degeneration by G.G. Kovacs (S162).
S.01.02 Antidepressants: are effects on emotion their primary mode of action? by S. Murphy; C.J. Harmer (S161).
PL.03.01 Epigenetic regulation of cognitive functions by I. Mansuy; K. Koshibu; J. Graeff (S159).
S.01.03 How antidepressants change emotional experience in depressed patients by P. Stein; R. Lanzenberger; S. Kasper (S161).
S.01.04 Steroid-monoamine interactions in emotion by R. Hurlemann; O.A. Onur; J. Kukolja (S161-S162).
S.01.05 How cortisol affects emotion by P. Putman (S162).
S.03.04 An alternative approach to antipsychotic activity: the metabotropic glutamatergic receptor by A. Weizman; A. Krivoy; T. Fischel (S165).
S.03.05 The muscarinic receptor family: potential targets for the treatment of symptoms associated with schizophrenia by C.C. Felder (S165).
S.05.02 Neuronal signaling and epigenetic mechanisms at the cognition-emotion interface by J.M.H.M. Reul (S168-S169).
S.04.08 Impulsive decision making predicts resistance to extinction of cocaine seeking and enhanced vulnerability to cue-induced relapse by N. Broos; A.N.M. Schoffelmeer; L. Diergaarde; T. Pattij; T.J. De Vries (S168).
S.05.03 The role of endocannabinoids in the amygdala in the regulation of emotional memory by P. Campolongo (S169).
S.05.04 Glucocorticoids and noradrenaline in severe stress exposure in humans by G. Schelling; B. Roozendaal; P. Campolongo; D. de Quervain (S169-S170).
S.05.05 D-cycloserine and exposure therapy by B. Rothbaum; M. Davis; K. Ressler (S170).
S.04.07 Behavioural and neurochemical consequences of 5-HT transporter deletion on 5-HT2C receptor functions in mice by C.B.P. Martin; C. Chevarin; K.P. Lesch; M. Hamon; L. Lanfumey; R. Mongeau (S168).
S.04.06 Altered aggressive behaviour following genetic and pharmacological manipulation of serotonin autoinhibition by E. Audero; B. Mlinar; Z. Skachokova; R. Corradetti; C. Gross (S167).
S.04.02 Lack of central serotonin synthesis: effects on development of GABAergic subpopulations by J. Waider; L. Gutknecht; K.P. Lesch (S166).
S.04.01 Identification of a mouse febrile seizure susceptibility gene by E.V.S. Hessel; M. de Wit; I.G. Wolterink-Donselaar; H.A. van Lith; M.J.H. Kas; P.N.E. de Graan (S165-S166).
S.04.03 Inositol monophosphatase: drug target or false alarm? by N. Singh; S. Vasudevan; J. Thomas; O. Kuznetsova; M. Knight; P. Aley; T. Sharp; G. Churchill (S166).
S.04.04 Stress-induced alterations in hippocampal and amygdalar microRNAs: effects of lithium by R.M. O'Connor; O.F. O'Leary; A. Dinan; A. Gokul; T.G. Dinan; J.F. Cryan (S166-S167).
S.04.05 Interactions of oligomeric and fibrillar b-amyloid with a7 neuronal nicotinic receptors and synaptic targets in Alzheimer's disease by A. Lilja; O. Porras; E. Storelli; A. Nordberg; A. Marutle (S167).
S.12.04 5-HT2C receptors and drug addiction by M. Filip; M. Zaniewska; A.C. McCreary (S182).
S.12.05 5-HT2C receptor ligands in the treatment of obesity and type 2 diabetes by L.K. Heisler; D.D. Lam (S182).
S.21.03 Psychotropic drugs and weight gain: which are the mechanisms? by U. Pagotto (S195).
S.21.02 The weight of the world: the burden and management of antipsychotic induced obesity by R.I.G. Holt (S195).
S.21.04 Arcuate NPY/AgRP neurons and the control of energy balance by S. Luquet; A. Joly; R. Denis; R. Palmiter; C. Magnan (S195-S196).
S.21.05 Antipsychotic-related metabolic and endocrine adverse events in pediatric patients: frequency, monitoring and management strategies by C. Correll (S196).
S.22.02 Alostatic load and oxidative stress in bipolar disorder by F. Kapczinski; K.M. Ceresér; M. Kauer-Sant'Anna (S196).
S.21.01 Weight gain and antidepressants: a meta-analysis clearly differentiates SSRIs differences by A. Serretti (S194-S195).
S.20.05 NIMH/FDA guidelines for clinical trials for cognition in schizophrenia: how much have we advanced? by S. Marder; R.W. Buchanan (S194).
S.20.01 Nicotinic receptors and the modulation of transmitter release in the prefrontal cortex by S. Wonnacott; P.D. Livingstone (S193).
S.19.05 Affective and cognitive aspects of pain processing in borderline personality disorder by C. Schmahl; I. Niedtfeld; I. Klossika (S192).
S.20.02 Alpha7 nicotinic receptors and synaptic plasticity by H.D. Mansvelder; R.B. Poorthuis; B. Bloem; K. Guillem (S193).
S.20.03 Nicotinic agonists in animal models of attention and working memory by M. Shoaib (S193-S194).
S.20.04 Alpha7 signalling pathways and their relevance to cognition by R. Roncarati (S194).
S.22.03 Neurocognition and psychosocial function in bipolar disorder by O.A. Andreassen; C. Simonsen; K. Sundet (S197).
S.22.04 Predictors of functioning in bipolar disorder by S. Dittmann; F. Seemüller; K. Hennig-Fast; R.R. Engel; M. Riedel; H.C. Grunze; W.E. Severus (S197).
S.24.05 Transgenic mouse models in addiction research by P. Robledo; E. Martín-García; A. Plaza-Zavala; F. Berrendero; R. Maldonado (S200-S201).
S.24.04 Endophenotypes of Disc1 missense mutations in mice by S.J. Clapcote; T.V. Lipina; J.C. Roder (S200).
S.25.01 Shared pathogenetic mechanisms of neurodegeneration between MS, stroke and neurodegenerative diseases by H. Lassmann (S201).
S.25.02 Ion channels and exhangers as potential targets for stroke therapy by L. Annunziato; G. Pignataro; O. Cuomo; P. Molinaro; F. Boscia; A. Scorziello; A. Secondo; A. Pannaccione; R. Sirabella; G.F. Di Renzo (S201).
S.25.03 Neuroprotection with minocyclin by Y. Lampl (S202).
S.24.03 Genotype-phenotype relationships for psychiatric disorders; gender effects by A. Heinz; E. Friedel; F. Schlagenhauf; I. Puls (S200).
S.24.02 Cognitive endophenotypes in schizophrenia by M.F. Aukes; B.Z. Alizadeh; C. Kemner; M.M. Sitskoorn; R.A. Ophoff; R.S. Kahn (S199-S200).
S.23.01 Risk factors for Alzheimer's disease by H. Soininen; A. Solomon; M. Kivipelto (S198).
S.22.05 Neurobiological correlates of treatment response to psychoeducation by F. Colom; I. Pacchiarotti; A. Murru; A.M.A. Nivoli; E. Vieta (S197-S198).
S.23.02 Cholinergic imaging with PET by C. Haense; K. Herholz (S198).
S.23.05 The role of the immune system in clearance of Abeta from the brain by J. Nicoll (S199).
S.24.01 Epigenetic effects on brain function and behaviour by L.S. Wilkinson; A.R. Isles; W. Davies; T. Humby (S199).
S.19.04 Altered pain processing in posttraumatic stress disorder by E. Geuze (S192).
S.19.03 Neurobiology of fear-induced analgesia by D.P. Finn; M. Roche; G.K. Ford; K. Rea; W.M. Olango; R.K. Butler; B. Harhen; S.M. Geranton; S.P. Hunt (S192).
S.15.04 Systems biology approaches to study Parkinson's disease in C. elegans models by G. Wong; M. Lakso; S. Asikainen; S. Vartiainen; L. Heikkinen; R. Nass (S185).
S.15.03 microRNA networks and neurodegenerative disease by S. Hébert (S185).
S.15.05 Network-based data integration for modifier gene and drug target discovery in Huntington's disease by C. Néri; C. Bicep; L. Mesrob (S185-S186).
S.16.01 Potential therapeutic targets from cellular/molecular signalling mechanisms in depression models by P. Svenningsson; T.M. Eriksson; K. Björk; S.O. Ögren; A. Mathe; M. El Yacoubi; J.M. Vaugeois (S186).
S.16.02 Targeting mechanisms of two differentially targeted serotonin receptors: dendritic 5-HT1A versus axonal 5-HT1B receptors by M. Darmon; S. Al Awabdh; J. Masson; M.B. Emerit (S186).
S.15.02 Modulation of dysregulated protein-protein-interactions in Huntington's disease by E.E. Wanker; M. Strödicke (S184-S185).
S.15.01 Data mining and neuroinformatics by F.A. Nielsen (S184).
S.14.02 Glutamatergic mechanisms in alcohol addiction by R. Spanagel (S183).
S.14.01 Shared and specific vulnerability in substance abuse by N. Ramoz; Y. Le Strat; P. Gorwood (S182-S183).
S.14.03 Predictors of relapse in alcohol dependence by U. Zimmermann (S183).
S.14.04 Role of glucocorticoids in alcoholism by H. Little (S183-S184).
S.14.05 Place for baclofen in treating alcoholism by G. Colombo; P. Maccioni; M.A.M. Carai; G.L. Gessa (S184).
S.16.03 PPARgamma as drug target for neurological and psychiatric diseases by L. Minghetti (S187).
S.16.04 Formation of N-acylethanolamines in the brain: where and when? by H. Hansen (S187).
S.18.03 Genetics of obesity by J. Hebebrand; A. Hinney; A. Scherag (S190).
S.18.02 Genetics of anorexia nervosa by D.A. Collier; C.M. Bulik; P.F. Sullivan (S190).
S.18.05 Neurobiological mechanisms of hyperactivity in anorexia nervosa by R.A.H. Adan; L.A.W. Verhagen; S.L. Dickson; E. Egecioglu; R.J. DiLeone (S190-S191).
S.19.01 Cerebral correlates of pain and depression by K.J. Bär; J. Terhaar; G. Wagner; M.K. Boettger (S191).
S.19.02 Emotional behaviour and pain in animal models by C. Becker; C. Rivat; A. Blugeot; B. Zeau; J.J. Benoliel (S191).
S.17.05 Can targeting circadian rhythym lead to better treatments for mood disorders? by C.H. Large; J. Huxley-Jones (S189).
S.17.04 Phase changes as correlates of clinical antidepressant response by F. Benedetti; S. Dallaspezia (S189).
S.16.05 N-acylethanolamines and motivated behaviour: focus on appetite disorders and alcoholism by F. Rodríguez de Fonseca; A. Bilbao (S187-S188).
S.17.01 Circadian rhythms: their role and dysfunction in affective disorder by A. Wirz-Justice (S188).
S.17.02 Translating molecular circadian findings into animal behaviour by H. Einat; N. Kronfeld-Schor (S188).
S.17.03 Pharmacological therapies of affective disorders influencing circadian rhythms by E. Corruble (S188-S189).
P.1.c.050 SRA-444: an example of early drug development decision based on a positron emission tomography study by M. El Gaaloul; S. Raje; A. Lieuwe; W.d. Hirst; T. Andree; S. Chalon (S263-S264).
P.1.c.051 Predictive modeling – impact of varying doses and different formulations on receptor occupancy profile for quetiapine by S. Nyberg (S264).
P.2.a.030 Deliberate self-harm and suicidal ideation in naturalistic outpatients: the Leiden routine outcome monitoring study by M.S. van Noorden; S. de Klerk; A.E. Giezen; P. Spinhoven; M.E. den Hollander-Gijsman; E.J. Giltay; A.E. Speckens; F.G. Zitman (S350-S351).
P.2.a.029 Pilot study on neurotrophin salivary levels in patients with major depression before and after escitalopram treatment by A. Iannitelli; E. Caroti; G. Bersani; I. Branchi; F. Cirulli; E. Alleva; L. Aloe; P. Tirassa (S350).
P.2.a.031 Prednisolone suppression test, but not dexamethasone predicts outcome in treatment resistant depression by M.F. Juruena; C.M. Pariante; A.S. Papadopoulos; L. Poon; S. Lightman; A.J. Cleare (S351-S352).
P.2.a.032 Amantadine: a treatment for major depressive disorder by A. Ruiz-Chow; J. Ramirez-Bermudez; L. Alviso-de la Serna; C. Rios (S352).
P.2.a.033 Therapy of anxiety-depressive disorders in outpatient cardiologic practice by N. Garganeyeva; A.I. Rozin; A.A. Evsyukov; D.S. Kaskayeva; A.V. Donov (S352-S353).
P.2.a.028 The effect of the number of depressive episodes on fatigue in female patients with major depression by P. Ferentinos; V.P. Kontaxakis; B.J. Havaki-Kontaxaki; D. Dikeos; G.N. Papadimitriou; L. Lykouras (S349-S350).
P.2.a.027 Effects of the serotonin type 3A receptor and the cytochrome 2D6*10 genes on citalopram efficacy and side effects in major depressive disorder by J. Paik; J. Kim; H. Ko; S. Lee; E. Kim (S349).
P.2.a.023 HPA axis hyperactivity is a vulnerability factor for switch to depressive disorder following interferon treatment by J. Eccles; C. Lallemant; F. Mushtaq; M. Greenwood; M. Keller; I. Haq; J. Tibble; R. Whale (S346-S347).
P.2.a.022 Current status of geriatric depression treatment in Korea by J. Paik; J. Kim; D. Moon; H. Ko (S346).
P.2.a.024 Quetiapine XR monotherapy and quetiapine XR+ongoing antidepressant versus lithium+ongoing AD for Stage II treatment-resistant major depressive disorder by M. Franco Martín; M.L. Figueira; P. Petrov; Z. Rihmer; L. Vavrusová; E. Dencker-Vansvik; L. Jörgensen; J. Köhler; M. Bauer (S347).
P.2.a.025 Dopamine transporter gene play a risk factor in patient with major depressive disorder? by C. Huang; M.J. Shy (S347-S348).
P.2.a.026 Superior efficacy results of agomelatine in a pooled analysis versus SSRI/SNRI by S. Kasper; A. Hale; P. Lemoine; M.A. Quera Salva (S348-S349).
P.2.a.034 Impact of methodology on the efficacy of extended release quetiapine fumarate in major depressive disorder by S. Montgomery; A. Kalali; R.S. McIntyre; W.R. Earley; S. Nyberg; H. Eriksson (S353).
P.2.b.001 Water extract of saffron (Crocus sativus) increases brain dopamine and glutamate concentration in the rat by J. Shams; M. Hedayati; F. Asefi; H. Sahraei (S353-S354).
P.2.b.010 Antidepressant-like features of mice with transgenic activation of Ras in differentiated neurons by O. Leske; Z. Bichler; R. Heumann (S358-S359).
P.2.b.009 Paroxetine and D-cycloserine attenuate deficits in cognitive processes following acute stress: an animal model of PTSD by J. Philbert; P. Pichat; B. BIton; G. Griebel (S358).
P.2.b.011 In search for a tool selectively evaluating depressive symptoms associated with different neurotransmitter systems by G. Faludi; X. Gonda; V. Bekes; V. Meszaros; A. Sarosi; A. Olah (S359-S360).
P.2.b.012 Transcriptional changes of BDNF and clock genes in the rat prefrontal cortex following acute agomelatine administration by F. Calabrese; R. Molteni; G. Guidotti; C. Gabriel; E. Mocaer; G. Racagni; M.A. Riva (S360).
P.2.b.013 Mice with decreased vesicular glutamate transporter VGLUT1 levels show an altered presynaptic 5-HT function by A.L. García-García; N. Elizalde; E. Venzala; J. Del Rio; L. Lanfumey; R.M. Tordera (S360-S361).
P.2.b.008 Effect of different antidepressants on behavioural alterations induced by chronic social defeat stress by E. Venzala; A.L. García-García; N. Elizalde; P. Delagrange; R. Tordera (S357-S358).
P.2.b.007 Time defining effects of tryptophan depletion on hormone secretion and brain 5-HT2 binding in the rat by M. Franklin; I. Bermudez; S. Mucha; N. Singewald; S. Gaburro; H. Murck (S357).
P.2.b.003 Control of murine affective behaviour in health and intestinal inflammation by the gut hormone peptide YY by E. Painsipp; H. Herzog; G. Sperk; P. Holzer (S355).
P.2.b.002 Risperidone, an atypical antipsychotic, enhances the effect of antidepressant drugs in animal models of depression by Z. Rogoz; K. Kaminska (S354).
P.2.b.004 Interconnectedness of homocysteine and affective disorders by S. Purvina; L. Kevere; D. Bauze; M. Zeibarts; A. Rizevs; S. Jelisejevs; M. Caune; I. Purvins; R. Andrezina (S355-S356).
P.2.b.005 The biological pathway underlying dysregulation of hippocampal 5HT1A-NR2B-GSK-3b function in major depression by D. Oh; S.H. Kim; Y.C. Park (S356).
P.2.b.006 Cognitive deficits and salivary cortisol in major depression: effects of treatment by K. Hinkelmann; S. Moritz; C. Muhtz; J. Botzenhard; K. Wiedemann; M. Kellner; C. Otte (S356-S357).
P.2.a.021 Factors influencing antidepressant adherence in the patients with depressive disorder by D.S. Moon; J.W. Paik; J.W. Kim; A.R. Cho (S345-S346).
P.2.a.020 Treatment of breast cancer patients with comorbid serious anxiety and depression by Z. Snoj; M. Primic Zakelj; I. Vucko Miklavcic; M. Licina; P. Pregelj (S344-S345).
P.2.a.002 The potential of the nicotinic channel blocker tc-5214 as augmentation treatment in patients with major depression by G. Dunbar; D. Hosford (S334).
P.2.a.001 Cyclothymic and hyperthymic temperaments in depressive patients by S. Goto; T. Terao; Y. Araki; N. Hoaki; Y.M. Wang; Y. Takai (S333-S334).
P.2.a.003 Three polymorphisms of endothelial nitric oxide synthase (eNOS) gene and plasma NO3 levels by A. Ikenouchi-Sugita; R. Yoshimura; T. Kishi; W. Umene-Nakano; H. Hori; K. Hayashi; A. Katsuki; N. Iwata; J. Nakamura (S334-S335).
P.2.a.004 Early improvement as a predictor of response to antidepressants in resistant depressive patients by M. Bares; T. Novak; M. Kopecek; P. Stopkova; J. Kozeny (S335).
P.2.a.005 Unplanned versus planned suicide attempters: motives, methods, and mental disorders in a Korea-based community sample by H.J. Jeon; J.Y. Lee; Y.M. Lee; J.P. Hong; S.H. Won; S.J. Cho; J.Y. Kim; S.M. Chang; H.W. Lee; M.J. Cho (S336).
P.1.i.010 Depression and anxiety pathway: diagnosis, treatment choice – illustration from Surrey UK by J. Rasmussen (S333).
p.1.i.009 Behavioural and neurochemical characterisation of central neuropathic pain after spinal cord transection in the rat by S. MDahoma; R. Massart; F. Chali; D. Orsal; C. Chevarin; V. Kayser; S. Bourgoin; M. Hamon (S332-S333).
p.1.i.005 Long-term functional effects on circadian rhythm caused by a single MDMA treatment by Z. Kátai; T. Garay; B. Balogh; E. Kirilly; G. Bagdy (S330-S331).
P.1.i.004 A randomized, three phase 34 week double-blind long-term efficacy study of extended-release methylphenidate in adults with ADHD by J. Biederman; E. Mick (S329-S330).
P.1.i.006 Clinical experience with electroconvulsive therapy at the university hospital in South Korea by H.C. Kim; S.W. Jung (S331).
P.1.i.007 Positive effects of an energy drink on driving performance during prolonged driving by M.A.J. Mets; S. Ketzer; C. Blom; M.H. Van Gerven; G.M. Van Willigenburg; B. Olivier; J.C. Verster (S331).
P.1.i.008 Functions and time scale of self-cutting in subjects suffering from borderline personality disorder by M. Muscionico; K. Dieben; R. Nicastro; N. Perroud; P. Huguelet (S332).
P.2.a.006 Predictors of remission in a national sample of patients with depressive disorders: the CRESCEND study by J.M. Kim; J.A. Yoo; S.J. Yang; S.W. Kim; I.S. Shin; J.S. Yoon; J.B. Kim; M.S. Lee; H.W. Lim; T.Y. Jun (S336-S337).
P.2.a.007 Comorbid physical disorders and 12 week treatment outcomes in Korean patients with depressive disorders by J.A. Yoo; J.A. Kim; S.J. Yang; S.W. Kim; I.S. Shin; J.S. Yoon; J.B. Kim; M.S. Lee; H.W. Lim; T.Y. Jun (S337).
P.2.a.016 Cytokine profile in treatment-resistant depression by L.A. Carvalho; J.P. Torre; A.J. Cleare; C.M. Pariante (S342-S343).
P.2.a.015 Transcranial direct current stimulation in patients with treatment-resistant major depressive episode by B. Dell'Osso; S. Zanoni; F. Castellano; C. Dobrea; B. Benatti; C. Arici; R. Ferrucci; M. Vergari; A. Priori; A.C. Altamura (S341-S342).
P.2.a.017 Acute deep brain stimulation in the subgenual cingulate alters REM sleep in patients with treatment resistant depression by C. Durant; A.L. Malizia; L. Paterson; A. Rich; D.J. Nutt; S. Gill; N.K. Patel; S. Wilson (S343).
P.2.a.018 Influences between defense mechanisms and antidepressants on the therapeutic compliance in major depressive disorder by D. Vasile; O. Vasiliu; M.L. Vasile; M. Terpan; A. Mangalagiu; V. Bogdan; D. Ojog; M.B. Petrescu; I. Paraico (S343-S344).
P.2.a.019 Memory and executive functions in patients treated with vagus nerve stimulation for refractory depression by V. Desbeaumes; F. Richer; E. LaGarde; S. Patry; A. Bouthillier; P. Lespérance (S344).
P.2.a.014 5-HTTLPR SS depressed women: higher baseline thyroid-stimulating hormone and lower antidepressant response by F. Gressier; S. Trabado; C. Verstuyft; P. Hardy; B. Fève; L. Becquemont; E. Corruble (S341).
P.2.a.013 Effect of escitalopram on depressive symptoms in patients with coronary artery stents by L.N. Yur'yeva; A.I. Mamchur; A.A. Dukelskiy (S340-S341).
P.2.a.009 Nonadherence to paroxetine; comparison between early-remitters and late-remitters by J. Nakamura; R. Yoshimura; A. Ikenouchi-Sugita; H. Hori; W. Umene-Nakano; A. Katsuki; N. Ueda (S338).
P.2.a.008 Gender differences in 12 week treatment outcomes in Korean depressive patients: a report of CRESCEND study by S. Yang; J. Yoo; K. Bae; J. Kim; I. Shin; S. Kim; J. Yoon (S337-S338).
P.2.a.010 The cortisol awakening response in patients remitted from depression by J.M. Aubry; F. Jermann; M. Gex-Fabry; L. Bockhorn; M. Van der Linden; N. Gervasoni; G. Bertschy; F.M. Rossier; G. Bondolfi (S339).
P.2.a.011 Cyclothymic and hyperthymic temperaments in depressive patients: supportive evidence for bipolar ii1/2 and iv3 by Y. Araki (S339-S340).
P.2.a.012 Do we treat different patients with different antidepressant? Clinical and economic assessments in Spanish setting by M. Blanca-Tamayo; A. Sicras-Mainar; B. Pascual-Arce; L. García-Sánchez; M.C. Pérez-Navarro; R. Navarro-Artieda; N. Muro-Perea (S340).
P.2.b.014 Desipramine reduces lipopolysaccharide-induced interleukin-1beta in brain and plasma of rats by E. Obuchowicz; A. Prymus; A.M. Bielecka; L. Drzyzga; M. Paul-Samojedny (S361).
P.2.b.015 Mediating role of psychological immune competencies on the development of susceptibility to depression by D. Pap; X. Gonda; J. Lazary; E. Molnar; L. Tothfalusi; G. Bagdy (S361-S362).
P.2.c.027 The effects of St. John's wort on premenstrual syndrome: a randomised double-blind, placebo-controlled study by H. Suh; J. Ryoo (S383).
P.2.c.026 Antidepressants for late-life depression: a meta analysis of placebo-controlled randomized trials by E. Tedeschini; Y. Levkovitz; G. Papakostas (S382-S383).
P.2.c.028 Effect of a single dose (50 mg) of agomelatine on bold fMRI responses to face emotion recognition in healthy volunteers by J. Lees; S. McKie; R. Dadhiwala; P. Horgan; G. Dawson; L. Seguin; E. Mocaër; J.F.W. Deakin (S383-S384).
P.2.c.029 Risk factors of drug interaction between warfarin and antidepressant in a clinical setting by R. Na; J.P. Hong; K.W. Kim; J.W. Choi; S.J. Park; K.K. Yi (S384).
P.2.c.030 Serum brain-derived neurotrophic factor levels as predictor of antidepressant therapy response by A. Eckert; M. Giese; J. Beck; S. Brand; F. Muheim; M. Hatzinger; E. Holsboer-Trachsler (S384-S385).
P.2.c.025 Effect of duloxetine on chronic tension-type headache in patients with major depressive disorder by H. Kim; K.J. Lee (S382).
P.2.c.024 Switching to second line antidepressant in the United Kingdom: main characteristics and determinants by J. Chollet; D. Saragoussi; N. Despiegel; K. Maman; D. Milea (S381-S382).
P.2.c.020 Effects of mirtazapine on brain-derived neurotrophic factor (BDNF) and catecholamine metabolites by A. Katsuki; R. Yoshimura; A. Sugita; H. Hori; W. Nakano; K. Hayashi; J. Nakamura (S379).
P.2.c.019 Polypharmacy in psychiatry: clinical practice versus empirical evidence by K. Lötscher; I.G. Anghelescu; S. Braun; R. Bridler; H.H. Stassen (S378-S379).
P.2.c.021 Agomelatine facilitates positive emotional processing in healthy volunteers by G.M. Goodwin; C. de Bodinat; G.R. Dawson; C.T. Dourish; L. Waldenmaier; S. Adams; P.J. Cowen; C.J. Harmer (S379-S380).
P.2.c.022 Twelve weeks of paroxetine treatment improves prefrontal brain activity. An fMRI study using the Tower of London by H.G. Ruhe; G. van Rooijen; D.J. Veltman; A.H. Schene (S380).
P.2.c.023 Sleep architecture in olanzapine treated patients with depression: a double blind randomized placebo controlled trial by R. Milev; L. Lazowski; A. Lowe; R. Jokic; R. du Toit (S380-S381).
P.2.c.031 Genotypic and phenotypic CYP2D6 poor metaboliser status in depressed patients treated with venlafaxine extended release by C. Kane; A. Nichols; V. Chhaya; G. Buckley; C. Guico-Pabia (S385-S386).
P.2.c.032 Adjunctive aripiprazole in major depressive disorder (MDD): efficacy and predictors of remission by J.C. Nelson; M.E. Thase; R.A. Baker; L.M. Rollin; R.D. McQuade; R.N. Marcus; R.M. Berman; S.R. Wisniewski; R. Gismondi; J.Y. Loze (S386).
P.2.d.002 Antidepressant activity of Iranian Corn Silk by M. Mahmoudi; S. Ehteshami (S392).
P.2.d.001 Antidepressant properties of ketamine plus imipramine treatment: behavioural and molecular studies in rats by G.Z. Réus; R.B. Stringari; K.F. Ribeiro; A.K. Ferraro; M.J.S. Frederico; M.F. Vitto; P. Cesconetto; C.T. Souza; J. Quevedo (S391).
P.2.d.003 The omega-3 polyunsaturated fatty acid docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia by K. Su; D.Y. Lu; Y.Y. Tsao (S392-S393).
P.2.d.004 The association of glucocorticoid receptor polymorphism with antidepressants treatment response in patients with major depressive disorder by M. Lee; H.S. Chang; Y.J. Jeong; S.J. Kim; H.Y. Lee; B.J. Ham (S393).
P.2.d.006 Role of PSA-NCAM in the structural plasticity associated to dopaminergic antidepressants in the medial prefrontal cortex by E. Castillo-Gómez; M.A. Gómez-Climent; C. García-Mompó; J. Nácher (S393-S394).
P.2.c.039 Noradrenergic uptake inhibition of higher doses of paroxetine in relation to clinical efficacy: the DELPHI-study by H.G. Ruhe; R. van Westrhenen; M.W. Koeter; M.C. Michel; H.H. Sitte; A.H. Schene (S390-S391).
P.2.c.038 Efficacy of levomilnacipran in improving symptoms and functional impairment associated with major depressive disorder by Y. Lecrubier; L. Mansuy; A. Bose; J. Li; P. Werner (S390).
P.2.c.034 Duloxetine versus sertraline in the treatment of post-stroke depression by E. Tzavellas; D. Karaiskos; K. Spengos; E. Economou; G.N. Papadimitriou; I. Liappas; T. Paparrigopoulos (S387).
P.2.c.033 Influence and interaction of genetic polymorphisms in serotonin system and early life stress on antidepressant response by Z.J. Zhang; Z. Xu; Y.Y. Shi; M.J. Pu; C.Y. Wang; Z.N. Liu; G.P. Reynolds (S386-S387).
P.2.c.035 Effect of phospholipase C enzyme gene and environmental factors on antidepressant treatment in Han Chinese population by Z.J. Zhang; Y.Y. Shi; Z. Xu; M.J. Pu; C.Y. Wang; Z.N. Liu; G.P. Reynolds (S388).
P.2.c.036 Associations of gene-gene interaction in the Ras-Raf-MAPK signal pathway with antidepressant drug response by Z.J. Zhang; C.J. Wang; M.J. Pu; Z. Xu; C.Y. Wang; Z.N. Liu (S388-S389).
P.2.c.037 The serotonin transporter (SERT) occupancy in median raphe nucleus quantified with PET predicts treatment response to SSRIs in major depressive disorder by E. Akimova; R. Lanzenberger; M. Savli; D. Häusler; W. Wadsak; C. Spindelegger; U. Moser; M. Fink; K. Kletter; S. Kasper (S389).
P.2.c.018 Safety of quetiapine for treatment of insomnia in patients with major depressive disorder by S. Lee; J.H. Han; S.C. Hong; J.H. Jeong; H.J. Seo; H.K. Lim (S377-S378).
P.2.c.017 Treatment insomnia associated with depression in patients suffering from malignant neoplasm by A. Vasylyeva; S. Tabachnikov (S377).
P.2.b.024 Lithium preferentially increases neurogenesis in the ventral but not dorsal hippocampus of stressed BALB/c mice by O.F. O'Leary; R.M. O'Connor; J.F. Cryan (S366-S367).
P.2.b.023 Rodent magnesium-deficiency models for depression and their relationship to NMDA receptor/Nitric Oxide pathways by N. Singewald; S.B. Sartori; S. Gaburro; C. Schmuckermair; A. Hetzenauer; A. Rjabokon; M. Franklin; I. Bermudez; H. Murck; J.H. Shin; L. Lin; G. Lubec; N. Whittle (S366).
P.2.b.025 Serotonin uptake in blood platelets is related to cingulate cortex activation by C. Kasess; C. Scharinger; G. Pail; Z. Uzelac; M. Freissmuth; S. Kasper; E. Moser; H. Sitte; L. Pezawas (S367).
P.2.c.001 Adding an atypical antipsychotic drug induced a rapid increase of plasma BDNF levels in refractory depression by R. Yoshimura; A. Ikenouchi-Sugita; H. Hori; W. Umene-Nakano; A. Katsuki; K. Hayashi; J. Nakamura (S367-S368).
P.2.c.002 Efficacy of paroxetine as monotherapy or in combination with sodium valproate in PTSD by G.S. Arslanagic; A. Kucukalic (S368).
P.2.b.022 Serum BDNF levels correlate with arousal status in women by G. Bersani; A. Iannitelli; P. TIrassa; F. Cirulli; I. Branchi; L. Aloe; E. Alleva (S365-S366).
P.2.b.021 Escitalopram in the treatment of depression by I. Duran; R. Gomez; P. Sanchez; T. Alvarez; A. Chinchilla; M. Vega; A. Cebollada; R. Manzanero; A. Regidor; M. Serrano (S365).
P.2.b.017 Defining endophenoypes in major depressive disorder: anhedonia, neuroticism and psychomotor speed by E. Vrieze; K. Demyttenaere; R. Bruffaert; M. Schmidt; P. de Boer; S. Claes (S362-S363).
P.2.b.016 Role of phosphodiasterase 4 variants in depression and therapeutic treatment by Y. Dwivedi (S362).
P.2.b.018 Mouse communal nest: early social enrichment blunts adult depression-like phenotype altering BDNF epigenetic structure by I. Branchi; I. D'Andrea; S. Santarelli; F. Cirulli; N. Karpova; E. Castrén; E. Alleva (S363-S364).
P.2.b.019 Agomelatine has antidepressant effects and modifies BDNF and neuronal plasticity markers in the rat PFC and hippocampus by M. Bianchi; C. Potard; N. Ladurelle; C. Gabriel; E. Mocaer; E.E. Baulieu (S364).
P.2.b.020 Changes in gene expression in the rat brain induced by partial serotonergic denervation and chronic variable by A. Alttoa; M. Kanarik; J. Harro (S364-S365).
P.2.c.003 Comparison of Citrus aurantium and imipramine for treatment of major depressive disorder by M. Maroufi; F. Kianvash; M.R. Alavi (S369).
P.2.c.004 Response to paroxetine and sodium valproate in PTSD: gender differences, efficacy and tolerability by G.S. Arslanagic; A. Kucukalic; S. Bise (S369-S370).
P.2.c.013 New functional variant in SLC6A4 gene as candidate of the individualised treatment of depression – the result of an RCT - by M. Kato; S. Tetsuo; M. Wakeno; S. Nonen; G. Okugawa; Y. Takekita; J. Azuma; T. Kinoshita (S374-S375).
P.2.c.012 Testosterone gel replacement improves sexual function in hypogonadal depressed men taking antidepressants by R. Amiaz; H. Pope; S.N. Seidman; M. Weiser (S374).
P.2.c.014 Agomelatine: a new therapeutic prospective in depression by C. Istikoglou; D. Foutsitzis; A. Vlavianou; P. Kanellos; N. Polonifis; D. Vlissides; K. Michelidakis; G. Theodorakopoulos (S375-S376).
P.2.c.015 Do our patients comply with antidepressant treatments? by J.I. Castro; S. Oller; M.I. Fernández; L.M. Martín; D. Flamarich; D. Lacasta; R. García; M.T. Font (S376).
P.2.c.016 Sertraline versus mirtazapine in treatment of depression in Parkinson's disease by G. Djokic; D. Pavicevic; N. Zivkovic; M. Nenadovic; N. Nenadovic; D. Duisin (S376-S377).
P.2.c.011 The effect of carbamazepine co-therapy on the extent of MAO-A inhibition by moclobemide in depressed patients by A. Rakic Ignjatovic; B. Miljkovic; D. Todorovic; I. Timotijevic; M. Pokrajac (S373-S374).
P.2.c.010 Comparison of BMI changes associated with various antidepressant treatments during acute depression by M.H. Kang; S.H. Chung; J.N. Bae; J.S. Lee; C.E. Kim (S373).
P.2.c.006 The effect of repetitive transcranial magnetic stimulation in major depressive disorder partial remission by C. Charnsil; S. Suttajit; V. Bunyanarutee; S. Lelaput (S370-S371).
P.2.c.005 Plasma homovanillic acid levels and 5-HTTLPR gene polymorphism are predictive factors for sertraline in Japanese depressed patients by W. Nakano; R. Yoshimura; N. Ueda; A. Suzuki; A. Ikenouchi-Sugita; H. Hori; K. Otani; J. Nakamura (S370).
P.2.c.007 Efficacy of mirtazapine in depressed outpatients with an enduring personality change after a catastrophic experience by M. Stojakovic; S. Medenica; B. Stojakovic; D. Trkulja; S. Vukadinovic; N. Selman; S. Ristic (S371).
P.2.c.008 Assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease by M. Mancini; G. Meco; G. Tedeschi; G. Fabbrini; P. Stanzione; F. Stocchi; R. Ceravolo; M. Guadagna; G. Dell'Agnello; U. Bonuccelli (S372).
P.2.c.009 The effect of major depression, SSRI and gepirone-extended-release treatment on sexual function in women by L. Fabre (S372-S373).
P.1.i.003 Examination of the effects of stimulant treatment across the adult lifecycle of adults with ADHD: a controlled study by J. Biederman; R. Fried; C. Petty; S. Faraone (S329).
P.1.i.002 Changes in cerebrospinal fluid insulin during non-neurological surgery by S. Bromander; R. Anckarsäter; B. Ahrén; M. Kristiansson; K. Blennow; H. Zetterberg; H. Anckarsäter; C. Wass (S328-S329).
P.1.d.021 Evaluation of the novel anxiolytic compound BNC210 in a rodent model of cholecystokinin-induced panic by S. O'Connor; B. Huyard; G. Kremmidiotis; S. Wagner; E. Andriambeloson (S285).
P.1.d.020 Role of interferon-gamma on anxiety-like behaviour in mice by V.M. Saito; D.H. Rodrigues; A.L. Teixeira; F.A. Moreira (S284-S285).
P.1.d.022 GABAergic synaptic coverage of principal cells in the hippocampus in the rat model of schizophrenia by N. Radonjic; I. Jakovcevski; V. Bumbasirevic; N. Petronijevic (S285-S286).
P.1.d.023 Effect of sex hormones on pain-related behaviour in rats by E. Shekunova; A. Malyshkin; I. Belozertseva (S286).
P.1.d.024 Acute behavioural effects of nicotine in male mice by I. Belozertseva (S287).
P.1.d.019 Circadian pattern of wheel running activity of four laboratory mouse strains by M. Ágoston; J. Wellmann; P. Delagrange; M. Spedding; I. Gacsályi; G. Szénási (S284).
P.1.d.018 Memory consolidation via membrane glucocorticoid receptors that can be blocked by cannabinoid receptor antagonists by D. Hauer; R.V. Fornari; P. Atsak; P. Campolongo; G. Schelling; B. Roozendaal (S283-S284).
P.1.d.014 HFS and pharmacological inactivation of the globus pallidus and nucleus entopeduncularis differentially affect quinpirole-induced compulsive checking in rats by A. Djodari-Irani; J. Klein; J. Banzhaf; G. Juckel; A. Heinz; A. Kupsch; R. Morgenstern; C. Winter (S281-S282).
P.1.d.013 Influence of D1 and D2 antagonists on mother-dependent behaviour of 10 and 15 days old albino rat pups by I. Stovolosov; V. Dubynin; A. Kamensky (S280-S281).
P.1.d.015 Postponed influence of neonatal arginine-vasopressin and the arginine-vasopressin fragment Ac-D-MPRG administration to young white rats on behaviour by P. Kim; O.G. Voskresenskaya; A.A. Kamensky; V.P. Golubovich (S282).
P.1.d.016 Acute effects of modafinil on affective behaviour in aggressive and timid male mice by A. Máchalová; D. Vrsková; K. Slais; A. Sulcová (S282-S283).
P.1.d.017 Dissociation between anhedonia, anxiety and brain BDNF levels in a mouse model of social stress by A. Berry; V. Bellisario; S. Capoccia; E. Alleva; P. Tirassa; F. Cirulli (S283).
P.1.d.025 The involvement of oxidative stress in some cognitive effects of angiotensin II and angiotensin 1–7 in rats by A. Ciobica; L. Hritcu; I. Haulica; R. Popescu; V. Bild (S287-S288).
P.1.d.026 Nicotine ameliorates behavioural deficits and oxidative stress in a 6-hydroxydopamine rat model of Parkinson's disease by A. Ciobica; L. Hritcu; V. Artenie; M. Padurariu; Z. Olteanu (S288).
P.1.e.010 The effect of COMT Val108/158Met Polymorphism on brain activations in response to negative affective facial stimuli by H. Byung-Joo; J. In-Kwa (S293-S294).
P.1.e.009 Delta9-THC induces non-specific psychotropic effects reflected in resting-state brain function: a pharmaco-imaging study by G. Jager; H.H. van Hell; M.G. Bossong; G. Kristo; R.S. Kahn; N.F. Ramsey (S293).
P.1.e.011 Fronto-limbic interaction of working memory and emotion in the medial prefrontal cortex by G. Pail; W. Huf; C. Kasess; S. Kasper; E. Moser; B. Brocke; A. Meyer-Lindenberg; V.S. Mattay; D.R. Weinberger; L. Pezawas (S294).
P.1.e.012 Is there a link between amygdala volume, cognitive function and childhood trauma in first-episode psychosis? by M. Aas; P. Dazzan; A. Gibbs; C. Morgan; H.L. Fisher; A. Reichenberg; J. Zanelli; K. Morgan; R. Murray; C.M. Pariante (S294-S295).
P.1.e.013 Irony comprehension in bipolar disorder: an fMRI study by M. Simon; E. Varga; A.S. Hajnal; G. Orsi; T. Tenyi; S. Fekete; R. Herold (S295).
P.1.e.008 Impact of genetic polymorphism on resting state functional connectivity in healthy subjects by M.S. Byun; W.H. Jung; J.H. Jang; D.H. Kang; S.J. Kwon; C.H. Choi; J.S. Kwon (S292-S293).
P.1.e.007 Abnormal cortical neurotransmitter levels in young people at familial risk of depression by M.J. Taylor; Z.N. Mannie; R. Norbury; J. Near; P.J. Cowen (S292).
P.1.e.003 White matter microstructure in transsexuals by E. Gómez-Gil; G. Rametti; B. Carrillo; C. Junque; S. Segovia; A. Gómez; A. Guillamon (S289).
P.1.e.002 Diffusion tensor imaging findings in early-onset schizophrenia patients by M. Gawlowska; P. Gebski; J. Rabe-Jablonska (S288-S289).
P.1.e.004 Effects of minocycline on regional cerebral blood flow in schizophrenia by C. Marque; C. Chaves; L. Wichert-Ana; J.A.S. Crippa; A.W. Zuardi; G.B. Baker; F.S. Guimarães; S.M. Dursun; J.E.C. Hallak (S290).
P.1.e.005 Delta9-tetrahydrocannabinol (THC) impairs working memory system capacity: a pharmacological MRI study by M.G. Bossong; H.H. van Hell; G. Jager; F.A. Oudman; R.S. Kahn; N.F. Ramsey (S290-S291).
P.1.e.006 Differential brain changes in males with early-onset psychotic disorders by diagnosis by C. Moreno Ruiz; M. Rapado-Castro; S. Reig; J. Castro-Fornieles; A. González-Pinto; J. Janssen; M. Parellada; I. Baeza; M. Desco; C. Arango (S291).
P.1.d.012 Individual differences in the expression of prepulse inhibition predict the magnitude of amphetamine sensitisation by D. Peleg-Raibstein; J. Hauser; L.L. Lopez; P.A. Gargiulo; J. Feldon; B.K. Yee (S280).
P.1.d.011 Effects of excitotoxic lesions of the CA1 region of the hippocampus on acquisition of a place and cue water maze task by N. Chkhikvishvili; M. Burjanadze; G. Maglakelidze; R. Sakandelidze (S279-S280).
P.1.c.060 Revisiting Max Hamilton's model of consensus ratings – a new approach to increase signal detection in CNS drug trials by R. Gaur; M. Sajatovic; N. Lee; L. Ramirez (S269-S270).
P.1.c.059 Role of acetylcholine-mediated neurotransmission within pedunculopontine tegmental nucleus in the post-ictal analgesia by R.C. de Oliveira; R. de Oliveira; N.C. Coimbra (S268-S269).
P.1.c.061 Long term effects of perinatal phencyclidine treatment on the cytochrome c oxidase activity in the rat brain by T. Nikolic; N. Radonjic; N. Petronijevic (S270).
P.1.c.062 Effects of glutamic acid on signaling and structural proteins of rat brain endothelial cells in ischaemic conditions by A. Malecki; J. Bernacki; K. Nierwinska; A. Pudelko; A. Dobrowolska (S270-S271).
P.1.c.063 Alpha-1-noradrenergic receptor blockade in OCD: an open label add-on study with prazosin by M. Figee; A. Klompmakers; D.A.J.P. Denys (S271).
P.1.c.058 Morphine microinjections in the substantia nigra, pars lateralis, increase fear evoked by inferior colliculus by R. de Oliveira; R.C. de Oliveira; N.C. Coimbra (S268).
P.1.c.057 Human psychopharmacology of the kappa opioid agonist salvinorin A by M.W. Johnson; R.R. Griffiths (S267-S268).
P.1.c.053 The effect of olanzapine on a tetrahydrocannabinol-induced increase on the positive and negative syndrome scale by H.D. Kleinloog; M. Liem-Moolenaar; G.E. Jacobs; M.L. de Kam; J.M.A. van Gerven (S265).
P.1.c.052 Effect of combination of ethanol with the orexin receptor antagonist almorexant or zolpidem on motor performance in rats by M.A. Steiner; H. Lecourt; C. Brisbare-Roch; F. Jenck (S264-S265).
P.1.c.054 Sustained administration of bupropion enhances serotonergic and noradrenergic neurotransmission in the rat hippocampus by R. Ghanbari; M. El Mansari; P. Blier (S265-S266).
P.1.c.055 Electrophysiological effects of sustained administration of trazodone on serotonin system by R. Ghanbari; M. El Mansari; P. Blier (S266-S267).
P.1.c.056 Opioid pathways between the inferior colliculus and dorsal periaqueductal grey matter modulate panic-like behaviours by A. Twardowschy; N.C. Coimbra (S267).
P.1.c.064 Decreased neuregulin-1 in the cortex of rat pups as immediate effect of perinatal phencyclidine treatment by N. Petronijevic; T. Nikolic; N. Radonjic; U. Vilimanovich; V. Trajkovic; V. Bumbairevic (S271-S272).
P.1.c.065 Neuroprotection signalling after electroconvulsive stimulation by D. Rosa; R. Souza; A. Barros; F. Lima; G. Feier; J. Quevedo; M. Romano-Silva (S272).
P.1.d.007 Effects of 6-hydroxydopamine lesioning of the medial prefrontal cortex on social interactions in rats by M.S. Choi; Y.M. Oh; Y.C. Chung (S277-S278).
P.1.d.006 Prenatal administration of analog of the AVP(6–9) analogue Ac-D-MPRG influences on the postpartum behaviour in white rats by O. Voskresenskaya; A. Kamensky; V. Golubovich (S277).
P.1.d.008 Diacylglycerol kinase β knockout mice show an abnormal response on psychostimulant-induced behavioural change by H. Hara; K. Kakefuda; M. Ishisaka; A. Oyagi; K. Tsuruma; M. Shimazawa; K. Yokota; N. Saito; K. Fukunaga; J. Takeda (S278).
P.1.d.009 Longterm memory formation in non-association learning task in sham-operated and dentate gyrus lesioned rats by T. Naneishvili; M. Dashniani; G. Beselia; A. Noselidze; L. Kruashvili (S278-S279).
P.1.d.010 Prenatal stress and alcohol produce obsessive-compulsive-like behaviour in mice by M.V. Morozova; N.K. Popova (S279).
P.1.d.005 The effects of ketoprofen and dexketoprofen soft matter vesicles in an experimental pain model in mice by L. Tartau; D. Bindar; V. Melnig (S276).
P.1.d.004 Cyclooxygenase-2 inhibition by nimesulide may reduce the incidence of pentylenetetrazole-induced seizure in mice by A. Mesdaghinia; A. Heydari; P. Khazaee; H. Yazdanpanah (S275-S276).
P.1.c.067 Effect of group II metabotropic glutamate receptor agonist on behaviour and electroencephalography in a model of psychosis by M. Fujakova; T. Palenicek; I. Gorman; M. Brunovsky (S273-S274).
P.1.c.066 Behavioural effects of intranasal dopamine administration by A. Amikishieva; A. Cholodar (S273).
P.1.d.001 Marinobufagenin, an endogenous Na pump inhibitor, is implicated in social behavior of mice by V.A. Kashkin; I.V. Belozertseva; E.V. Shekunova; E.E. Zvartau; A.Y. Bagrov (S274).
P.1.d.002 Effect of semi-purified constituent from guaraná seeds on performance of rats in elevated T maze by E.A. Audi; C.M. Roncon; C.B. Almeida; J.C.P. Mello (S274-S275).
P.1.d.003 Advantageous effect of deramciclane in the NaN3 model of Alzheimer's disease in rats by K. Megyeri; K. Móricz; I. Nagyné-Gyönös; M. Albert; I. Gacsályi (S275).
P.1.e.014 Study on auditory hallucination and delusion using single photon emission computer tomography in schizophrenia by S.K. Wang; J.G. Lee; I.S. Chee; J.L. Kim; S.M. Kim; Y.D. Seo (S296).
P.1.e.015 Emotion cognition interaction located using surface-based versus volume-based analysis by W. Huf; G. Pail; B. Hartinger; C. Kasess; S. Kasper; V.S. Mattay; A. Meyer-Lindenberg; E. Moser; D.R. Weinberger; L. Pezawas (S296-S297).
P.1.g.017 American ginseng improves human neurocognitive function: a randomized, double-blind, placebo-controlled, crossover study by A. Scholey; A. Ossoukhova; L. Owen; A. Pipingas; M. Kras; A. Ibarra; C. Stough (S318).
P.1.g.016 Nitric oxide donor sodium nitroprusside facilitates induction of long-term potentiation in the dentate gyrus by N. Dolu; S. Artis; C. Suer; S. Aydogan; L. Sahin; S. Bitiktas (S317).
P.1.g.018 Genetic, neurophysiologic and behavioural factors in human risk taking behaviour: an endophenotype by I. Heitland; R.S. Oosting; J.M.P. Baas; J.L. Kenemans; K.B.E. Böcker (S318-S319).
P.1.g.019 The effect of acute cold stress on long term potentiation in rats by A.S. Artis; N. Dolu; L. Sahin; A. Cetin; C. Suer (S319).
P.1.g.020 Computerised cognitive testing in schizophrenia: patients' experiences by S. Pandey-Bhat; G. Nath; A. Arneja; A. Sharma; H. Kaviani; S. De Santi (S319-S320).
P.1.g.015 A cognitive behavioural therapy group treatment program for body dysmorphic disorder: preliminary results by C.A.B. Molenaar; N.C.C. Vulink; D.A.J.P. Denys (S316-S317).
P.1.g.014 Cognitive and neurophysiological performance following scopolamine and ketamine administration in a crossover study by N. Levy-Cooperman; D. Milovan; A. Reches; N. Pinchuk; M.K. Romach; G. Ben Bashat; R. Shani-Hershkovitch; L.Y. Deouell; A.B. Geva; E.M. Sellers (S316).
P.1.g.010 Precuneus hypoperfusion plays an important role in memory impairment of patients with systemic lupus erythematosus by D. Oh; S.H. Kim; Y.Y. Choi; J. Choi (S314).
P.1.g.009 Evaluation of an emotional tone discrimination task in humans as a potential method for assessing cognitive bias by M.H. Anderson; E.S.J. Robinson; M.R. Munafo (S313-S314).
P.1.g.011 Assessing cognitive impairment to define needs for care in a sample of chronic outpatients with schizophrenia by G. Cerveri; V. Venturi; L.S. Volonteri; A. Mazzocchi; C. Mencacci (S314-S315).
P.1.g.012 Functional cognitive consequence of modulating adult hippocampal neurogenesis in the rat by P.J.D. Goetghebeur; R. Dias (S315).
P.1.g.013 Chronic pravastatin but not atorvastatin impairs cognitive function in two rodent models of learning and memory by S.A. Stuart; J.D. Robertson; N.V. Marrion; E.S.J. Robinson (S315-S316).
P.1.g.021 Comparison of AChE inhibition/5-HT1A blockade in healthy subjects in a scopolamine model of cognitive impairment by V. Parks; A. Patat; S. Raje; K. Wesnes; P. Boeijinga (S320).
P.1.g.022 Decision-making in euthymis bipolar disorders: their relationship with suicidal behaviour by D.J. Martino; S.A. Strejilevich; T. Torralva; F. Manes (S320-S321).
P.1.h.007 Influence of compensation satisfaction on change of health-related quality of life after a flood by S. Min; Y. Joe; M. Kim; J. Heo; J. Shin; S. Koh (S326).
P.1.h.006 Detection of substances of abuse in emergency department: is there an increasing the use of benzodiazepines? by M. Mola Gibert; R. Pou Calvo; L. Montesinos Rueda; E. Gine Serven; A. Alvarez Gomez; E. Batlle de Santiago (S325-S326).
P.1.h.008 Aggression on a psychiatric acute ward: predictors and clinical assessments by M. Stinga; C. Papastergios; K. Papanikolaou; E. Papageorgiou; M. Ntavou; N. Voura; G.F. Angelidis (S326-S327).
P.1.h.009 Absolute risk versus risk ratio in Framingham scoring algorithm for prevention of cardiovascular risk by C. Brambilla; C. Siu (S327).
P.1.i.001 Sublingual 3.5mg zolpidem for middle-of-the-night insomnia: no tolerance, rebound or increase in use over 4 weeks by T. Roth; N.N. Singh; F. Steinberg; E. Li (S328).
P.1.h.005 Sleep quality and depression among nursing home residents by F.O. Orhan; D. Tuncel; F. Tas; N. Demirci; A. Özer; M.F. Karaaslan (S325).
P.1.h.004 Health-related quality of life of psychiatric disorders and somatic disorders in a nationwide sample of South Korea by S.J. Cho; J.P. Hong; S. Chang; J.Y. Lee; M.J. Cho (S324-S325).
P.1.g.024 The influence of corticosteroid receptors on olfactory fear conditioning by R.R. Souza; A.P. Carobrez (S322).
P.1.g.023 No evidence of differences in neurocognitive functioning among euthymic bipolar I and bipolar II disorders by D.J. Martino; A. Igoa; E. Marengo; G. Fassi; S.A. Strejilevich (S321-S322).
P.1.h.001 Comparison of treated and untreated major depressive disorder in a nationwide sample of Korean adults by K. Kim; S. Park; J.W. Choi; J.I. Park; J.P. Hong; M.J. Cho (S322-S323).
P.1.h.002 A different psychiatric diagnosis with similar economic impact in primary care setting: comorbidity and associated cost by M. Blanca-Tamayo; A. Sicras-Mainar; B. Pacual-Arce; N. Muro-Perea; R. Navarro-Artieda; L. García-Sánchez; M.C. Pérez-Navarro (S323).
P.1.h.003 Prevalence of metabolic syndrome and cardiovascular risk in patients with schizoaffective disorders by A. Benabarre; M.P. García-Portilla; L. Livianos; F. Mesa (S323-S324).
P.1.g.008 Cognitive effects of electrode placement and stimulus dose in brief-pulse electroconvulsive therapy for depression by M. Semkovska; O. Babalola; D. Keane; D.M. McLoughlin (S312-S313).
P.1.g.007 Experimental hyperthyroidism disrupts hippocampal long-term potentiation but not paired pulse facilitation in adult rats by C. Süer; N. Dolu; S. Artis; E. Taskin; L. Sahin (S312).
P.1.e.025 Dysfunctional reward circuitry in obsessive-compulsive disorder by M. Figee; M. Vink; F. de Geus; N.C.C. Vulink; D.J. Veltman; H.G.M. Westenberg; D.A.J.P. Denys (S302).
P.1.e.024 Effect of antidepressant treatment on the neural circuitry in dysthymia: a functional magnetic resonance imaging study by A. Ravindran; A. Smith; T. Georgescu; C. Cameron; R. Bhatla; M. Hogan (S301-S302).
P.1.e.026 [11C]AF150(S): a putative agonist PET ligand for in vivo imaging of the M1 muscarinic acetylcholine receptor by J.E. Leysen; J.C. Buiter; A. Fisher; M.C. Huisman; M. Yaqub; R. Boellaard; A.A. Lammertsma; A.D. Windhorst (S302-S303).
P.1.e.027 Voxel-based morphometry in affected and unaffected offspring of bipolar parents by T. Novak; M. Kopecek; J. Horacek; T. Hajek; C. Hoschl (S303).
P.1.e.028 Increase of whole brain volume and gray and white matter tissue in OCD: a volumetric and voxel-based morphometry MRI study by T. Sobanski; G. Wagner; G. Peikert; U. Gruhn; H. Sauer; R.G. Schlösser (S303-S304).
P.1.e.023 Dopaminergic activity in Tourette's syndrome and obsessive-compulsive disorder by F.E. de Vries; D. Denys; D.C. Cath; M. Figee; D.J. Veltman; T.F. van der Doef; R. Boellaard; A.J.L.M. Balkom; A.A. Lammertsma; B.N.M. van Berckel (S300-S301).
P.1.e.022 Cathechol-O-methyltransferase genotype biases neural correlates of empathy and perceived personal distress in schizophrenia by S. Poletti; D. Radaelli; R. Riccaboni; R. Cavallaro; S. Smeraldi; F. Benedetti (S300).
P.1.e.017 Delta9-THC causes alterations in impulse regulation-related brain function: new insights from a pharmaco-imaging study by K. Noorman; H.H. van Hell; M.G. Bossong; N.F. Ramsey; G. Jager (S297-S298).
P.1.e.016 Cortisol awakening response and cerebral serotonin transporter binding by V.G. Frokjaer; D. Erritzoe; P. Jensen; J. Madsen; W. Baaré; G.M. Knudsen (S297).
P.1.e.018 Focal and global brain measurements in non-psychotic siblings of patients with schizophrenia by H. Boos; W. Cahn; N.E.M. Van Haren; E.M. Derks; R.M. Brouwer; H.G. Schnack; H.E. Hulshoff Pol; R.S. Kahn (S298-S299).
P.1.e.019 Acute administration of the anti-psychotic sulpiride modulates the neural response to chocolate in healthy volunteers by C. McCabe; A. Huber; C.J. Harmer; P.J. Cowen (S299).
P.1.e.021 In vivo assessment of changes in serotonin release in the non-human primate brain using PET and [11C]AZ10419369 by S.J. Finnema; A. Varrone; T.J. Hwang; L. Farde; C. Halldin (S299-S300).
P.1.e.029 Adolescent stress alters in vivo brain proton magnetic resonance parameters: relevance for impulse-control disorders by E.M. Marco; R. Canese; W. Adriani; F. Podo; G. Laviola (S304).
P.1.e.030 Clinical response of neuronavigated repetitive-TMS in the treatment of auditory hallucinations by M. Klirova; J. Horacek; T. Novak; J. Cermak; B. Tislerova; J. Tintera (S304-S305).
P.1.g.003 Cognitive and perceptual processing in body dysmorphic disorder by K. Jefferies; K. Laws; G. Hranov; N.A. Fineberg (S309-S310).
P.1.g.002 Results of adapted sex offenders therapy (SOTSEC-ID) in learning disabled sex offenders in a forensic hospital in UK by P. Kundi; R. Magombedze; D. Sharma (S309).
P.1.g.004 Deficit in interval timing as a candidate endophenotype for ADHD: evidence from time reproduction and estimation tasks by S. Gau; S. Hwang (S310).
P.1.g.005 Frontal lobe functions in patients with juvenile myoclonic epilepsy treated with valproate or lamotrigine by N. Jovic; D.M. Vucinic; V.A. Milovanovic (S311).
P.1.g.006 Cognitive function in hepatitis C patients: effect of pegylated interferon a and ribavirin therapy by M. Abd el Meguid; M. Moussa (S311-S312).
P.1.g.001 A prospective investigation of postconcussional symptoms after mild traumatic brain injury by R. Hou; R. Peveler; R. Moss-Morris; A. Belli; S. McVeigh; B. Bradley; K. Mogg (S308-S309).
P.1.f.005 Risk of development of premenstrual symptoms is associated with a traitlike negative bias in perception of life events by X. Gonda; K.N. Fountoulakis; G. Csukly; T. Telek; D. Pap; Z. Rihmer; G. Bagdy (S308).
P.1.f.001 Temperament and character profiles in female fibromyalgia syndrome patients and healthy controls by Ö. Altunören; F.O. Orhan; V. Nacitarhan; A. Özer; M.F. Karaaslan; O. Altunören (S305-S306).
P.1.f.002 Personality and help-seeking attitudes of people with mental health problems by K. Krysta; J. Brzezicki; S. Lech; M. Janas-Kozik; A. Klasik (S306).
P.1.f.003 Psychopathology assessment of fifty patients with morbid obesity who applied for bariatric surgery by E. Perez Martinez; C.J. van der Hofstadt; S. Tirado Gonzalez; M. Mateu Vicente (S306-S307).
P.1.f.004 Communal nest reduces vulnerability to depression-like behaviour and enhances brain dopamine function in adult male mice by I. D'Andrea; S. Santarelli; E. Alleva; I. Branchi (S307).